Analysis of urinary lipid biomarker candidates from tuberculosis patients by multiple reaction monitoring by Waldron, Elizabeth Louise
1                                                                     MSc by Elizabeth Louise Waldron, University of Cape Town 
 
Analysis of Urinary Lipid Biomarker Candidates from Tuberculosis Patients by Multiple Reaction Monitoring 
 
 
 Elizabeth Louise Waldron (WLDELI001) 
 
SUBMITTED TO THE UNIVERSITY OF CAPE TOWN 
In fulfilment for the degree: 
MSc (Med) Chemical Biology 
Faculty of Health Sciences 
UNIVERSITY OF CAPE TOWN 
 
February 2019 
Supervisor:  Professor Jonathan Blackburn 
   Department of Integrative Biomedical Sciences 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
2    MSc by Elizabeth Louise Waldron, University of Cape Town 
Name: Elizabeth Louise Waldron
Student Number: WLDELI001
Course: IBS5003W
Declaration 
I know that plagiarism is wrong. Plagiarism is to use another’s work and pretend that it is one’s own. 
I have used the American Psychology Association convention for citation and referencing. Each 
contribution to, and quotation in, this project from the work(s) of other people has been attributed, 
and has been cited and referenced.  
This project is my own work. 
I have not allowed, and will not allow, anyone to copy my work with the intention of passing it off as 
his or her own work.  
Signature ______________________________ 
Date __________________________________ 25/07/2019
3                                                                     MSc by Elizabeth Louise Waldron, University of Cape Town 
 
Acknowledgements 
First and foremost, I would like to thank my husband, James Ross, who has been nothing but 
supportive of me achieving this goal. He has brought home cooked dinners to the office when I’ve had 
to be there until the early hours of the morning, he has delivered lunch to me on the weekends when 
I’ve been stuck in the laboratory and has been enthusiastic about listening to me ramble on about this 
project. His patient support has made this project strides easier. I would like to thank my parents, 
Howard and Miranda Waldron, who have encouraged me and believed in me through the difficulties 
of this project. I would especially like to thank my father, Dr Howard Waldron, for mentoring me 
through the writing up phases and for using his scientific writing expertise to finely tune this thesis.   
This degree would not be possible if it were not for the opportunity granted to me by the Centre for 
Proteomic and Genomic Research (CPGR). I would like to thank them for generously funding this 
degree and for letting me work part-time for the duration of this degree. I would especially like to 
thank my manager, Dr Liam Bell, for his understanding when I was absorbed in this thesis, and for his 
practical advice. I would also like to thank him for his contributions in reviewing this report. I would 
further like to thank the rest of the team at the CPGR, namely Michelle du Plessis, who picked up my 
workload with no complaints. This was a great comfort and freed me up to focus on my masters.  
The students of the Blackburn Laboratory have been instrumental in me completing this degree, 
whether it be help with the machines, or just a laugh over lunch. I would especially like to thank 
Alexander Giddey and Brandon Murugan who were always willing to help me rearrange equipment in 
the laboratory and gave me practical advice and guidance without which this project would not be 
half of what it is today. Thank you to Dr Zandile Mlamla who has mentored me and taught me the 
ways of lipids. She provided fundamental advice on chromatography and lipidomic sample 
preparation techniques. She was incredibly patient with my questions and made this work go 
smoothly. Thank you to Dr Bridget Calder who has provided much advice on multiple reaction 
monitoring and practical help by keeping the machines of the laboratory running and in good 
condition. I would also like to thank her for her contributions in reviewing this report. I would like to 
extend my gratitude to my supervisor, Professor Jonathan Blackburn, for being so encouraging 
throughout this degree. I had moments of panic where I did not believe in myself, and I always felt 
heaps better after a meeting with Prof. I would like to thank him for his patience and for his calm 
wisdom; his guidance kept me going and kept my eye on the target.    
Finally, I would like to thank God for giving me faith to keep me grounded through the trying times. I 
am eternally grateful for my community of friends, particularly Cindy Adriaanse, who have kept my 
life balanced and inspired me to just stop and smell the roses.   
4                                                                     MSc by Elizabeth Louise Waldron, University of Cape Town 
 
Abstract 
Background: Tuberculosis (TB) is an aggressive disease and is the leading cause of death by infectious 
disease in South Africa. With early diagnosis and correct treatment, almost all TB cases can be cured. 
The main diagnostic tests in South Africa are limited for people living in rural areas, require sputum 
which cannot be produced by very ill patients, and have low sensitivity in immune compromised 
individuals. There is an urgent need for a non-invasive and robust diagnostic test which uses an easily 
accessible biofluid and can be performed at the point-of-care. Urine has shown promise as a diagnostic 
biofluid for biomarker investigation. Full scan mass spectrometry is the gold standard for the unbiased 
discovery of biomarker candidates, and targeted multiple reaction monitoring (MRM) is the method 
of choice for subsequent validation of biomarker candidates. A list of candidate urinary biomarkers 
has previously been generated which can discriminate between latent and active TB infection using 
MS1 mass spectrometry, but these biomarkers have not yet been verified by targeted mass 
spectrometry.   
Aims and Objectives: The aim of this project is to verify a list of biomarker candidates using MRM 
assays by: 1) developing MRM assays for known fatty acid standards, and 2) developing MRM assays 
for unidentified urinary lipid biomarker candidates de novo, which can be applied to clinical cohorts 
for future validation.   
Methods: Fatty acid standards were initially assessed using direct infusion full-scan MS1 mass 
spectrometry on an orbitrap mass analyser. They were then optimised for fragmentation by 
compound optimisation on a triple-quadrupole mass analyser, the data from which was used to build 
MRM assays. Liquid chromatography was optimised for these lipids and the MRMs were validated by 
spiking the lipid standards into a complex mixture.  
For the second part of the project, lipid extract (containing unidentified biomarker candidates) from 
patient derived urine samples were analysed by data-dependent acquisition with inclusion lists on an 
orbitrap mass analyser. From this experiment MS/MS data was acquired for biomarker candidates 
which were then compiled into MRM assays and verified using a triple-quadrupole mass analyser.  
Results: From six fatty acid standards, reliable MRM assays were generated for five of them. The 
biomarker candidates formed a list of 70 molecules which were further refined to 10 molecules which 
were reproducibly measured by MRM assay.  
Discussion and Conclusions: From this work the fatty acid standards can be used as internal retention 
time predictors for future lipidomic work and quality checks, as they eluted across a wide retention 
time range. The biomarker candidates have been verified using MRM assays and can be validated in 
larger clinical cohorts in the future. The end-goal is to use these biomarker candidates as part of a 
panel which represents a unique biosignature according to the disease state of the patient.    
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Chapter 1 – Improved biomarkers for tuberculosis diagnosis 1.1 Tuberculosis diagnosis in South Africa 
Tuberculosis (TB) is a disease caused by the bacterium Mycobacterium tuberculosis (Mtb) and is the 
leading cause of death by infectious disease in South Africa (StatsSA, 2015). In South Africa around 
80% of the population is estimated to be infected with Mtb but do not display symptoms and are 
therefore classified as having a latent TB infection (National South African AIDS council, 2011). Around 
454,000 South Africans progress to active TB infection every year and just over half of these patients 
are dually infected with human immunodeficiency virus (HIV) (World Health Organisation, 2015). With 
early diagnosis and correct treatment, almost all TB cases can be cured. Therefore, efforts to improve 
the diagnosis of TB are of utmost importance in tackling this epidemic. 
In South Africa there are three main diagnostic TB tests that are currently in use. The most sensitive is 
the culture test whereby a patient sputum sample is sent to a laboratory where it is cultured to 
determine the presence of Mtb. A positive result can be confirmed after ten days and a negative result 
can only be confirmed after 42 days (Davies & Pai, 2008). The shortcomings of this test are that it can 
only be conducted in centralised laboratories, meaning patients must travel for the test, the test is 
time consuming, and it is costly. The second is the sputum microscopy test which is widely used in 
Africa. Patient derived sputum is acid stained and subsequently evaluated under a microscope for the 
presence of Mtb cells. The test is inexpensive; however, it is labour intensive which means a limited 
number of smear tests can be conducted in a single day. The test also has a low sensitivity rate of just 
60% (Cattamanchi et al., 2009). Another diagnostic test is the Gene Xpert® MTB/RIF test (Cepheid, 
Sunnyvale, United States of America) which is a cartridge-based nucleic acid amplification test for Mtb 
in sputum and its resistance to the antibiotics (Steingart et al., 2014). The test does this by detecting 
specific sequences of bacterial deoxyribose nucleic acid (DNA) and it only takes two hours to produce 
a result. This test has limited availability to people living in rural areas as the instruments that conduct 
the test are centralised, and the cost per assay is still relatively high. All these tests are challenging for 
infants, the elderly, and people living with HIV as they are unable to produce a sputum sample. 
Additionally the tests have high false negative rates for people living with HIV as their sputum 
generally has low levels of bacteria (Bévilacqua, et al., 2002). The requirement of patient derived 
sputum places the health practitioners at risk of contracting a TB infection, and as a result all samples 
need to be processed in biosafety level three (BSL3) laboratories which are highly specialised and 
costly to set up.   1.2 TB biomarker research 
There is an urgent need for a non-invasive and robust diagnostic test which can be routinely 
performed at the point-of-care. Because of the challenges associated with collecting sputum, such a 
test should ideally be conducted on more easily accessible samples such as blood, breath, saliva, or 
urine. There are several TB disease states and the ideal test would differentiate one from the other. 
The defined clinical groups are patients who are naturally immune to TB, patients who have become 
immune by vaccination, patients who have active TB, patients who are at risk of developing active TB, 
patients who have a latent TB infection, or patients who are responding positively or negatively to TB 
treatment (Goletti et al., 2018).  In theory, each of these health-states possesses a unique biosignature 
which is yet to be discovered, tested and validated in well-characterised patient cohorts. Variables 
independent of disease state, inter alia, genetic and environmental factors, coinfections, exposure to 
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non-TB mycobacteria, nutritional status, metabolic status, and age must be considered when 
investigating biosignatures. 
There are two approaches to studying biomarkers; either Mtb-specific antigens can be targeted, or 
host response markers can be monitored.  
Urine has shown promise as a diagnostic biofluid with a clinically approved rapid urinary test that 
screens for lipoarabinomannan (LAM), a glycolipid found in the membrane of Mtb cells. LAM enters 
the urine through haematogenous TB dissemination, a condition which occurs primarily in HIV-
positive patients with advanced immunodeficiency (Lawn & Gupta-Wright, 2015). Thus LAM detection 
in urine is a suitable biomarker for disease severity and mortality among HIV positive patients, but it 
is not useful as a routine diagnostic biomarker (Drain et al., 2017). Urine has shown further potential 
as a suitable biofluid through a shotgun proteomics experiment, where Mtb proteins and differentially 
expressed human proteins were discovered as potential biomarker candidates in the urine of patients 
with active and latent TB infections (Young et al., 2014). 
Blood is the most researched biofluid and contains numerous human cytokines (Chegou et al., 2016) 
and has even been shown to contain detectable Mtb antigens (Liu et al., 2017). While the greatest 
need is for a first-line diagnostic test, many of the blood-based methods are suitable for assessing 
patient response to anti-TB treatment (Sweeney et al., 2017). Most diagnostic tests require centralised 
laboratory equipment, however some show promise of being conducted at the point of care for 
relatively low cost (Corstjens et al., 2016). Host response can be monitored in the blood to diagnose 
active TB infection (Jones et al., 2017) or to predict TB disease progression from latent to active (Zak 
et al., 2017; Khaliq et al., 2018). 
Two research groups have tested a handheld, point-of-care electronic nose to diagnose TB in exhaled 
breath (Teixeira et al., 2017; Zetola et al., 2017). The electronic nose will not satisfactorily replace the 
gold standard diagnoses because Mtb culture is needed for determination and drug susceptibility 
testing; however, it is an example of how biomarkers can be used as a point-of-care screening tool 
which would lessen the burden on centralised facilities.  
None of these methods have been approved for use in the public sector and there is an urgent need 
for current methods to be advanced so that they are field-ready, or for new methods to be 
developed.  1.3 Biomarker discovery and validation 
A biomarker is defined as anything that can be measured and used to predict a biological or diseased 
state (Strimbu & Tavel, 2010). A biomarker can be anything from number of cigarettes smoked per 
day, to a genetic mutation, or a protein fold change measured in blood. The platforms for biomarker 
discovery and validation are broad and varied, depending on the candidate biomarker(s), the species, 
and the disease. This thesis describes chemical and immunological compounds for biomarker 
investigation and therefore mass spectrometry is the platform of choice given its greater analytical 
specificity in these fields. Mass spectrometers are rare in clinical settings because it is a difficult 
application to automate, they are costly, and they have relatively low throughput compared with 
other analysers (Crutchfield et al., 2016). At this stage however, mass spectrometers can be used at 
the research level as accurate screening tools for the discovery, verification and validation of 
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biomarkers. Ideally, biomarker development is a phased approach that gradually shifts from unbiased 
characterisation by mass spectrometry to candidate-driven assays (Rifai et al., 2006).  
There are various methods for the discovery of biomarkers, however most methods require prior 
knowledge of the biomarker candidates, for example immunoaffinity capture. Mass spectrometry is 
currently the method of choice for the unbiased discovery of candidate biomarkers. Despite its 
superior sensitivity and specificity, mass spectrometry comes with a set of challenges that must be 
managed. First, the complexity and dynamic range of biofluids interfere with the low-abundant 
analytes which may result in them never being measured or detected in the discovery phase. It is 
unfortunately anticipated that disease biomarkers lie in this range of low-abundance analytes. This 
dynamic range issue can be addressed with multiple fractionation steps prior to mass spectrometry 
analysis and this introduces the second challenge which is the potential for high variation between 
experiments. This problem can be addressed with higher sample numbers and technical repeats 
(Cominetti et al., 2016).  
For a sample to be analysed by mass spectrometry it must first be ionised; the two routinely used 
methods are matrix assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI). ESI 
is considered a “soft” ionisation method that disperses highly charged droplets near atmospheric 
pressure, followed by droplet evaporation allowing the charged analytes to enter the mass 
spectrometry source (Smith et al., 1990).  
Mass accuracy largely depends on the resolution of the mass spectrometer. Resolution (or resolving 
power) is defined as the ability of a mass analyser to distinguish two separate ions with a small m/z 
difference. For example, high resolution mass spectrometers are able to resolve isotopes from each 
other, while low resolution machines will report an average mass measurement. Resolving power can 
be calculated using one or two peaks (de Hoffman & Stroobant, 2007):  
If two peaks are measured, then resolving power R = m/Δm; where m is the mass of one peak and Δm 
is the smallest difference between the two peaks.  
If just one peak is used, then the resolving power is the full width of the peak at half of the maximum 
height of the peak; R = FWHM.  
Discovery experiments – also called shotgun experiments – aim to capture as many measurements as 
possible in a given sample. A common acquisition method is data-dependent acquisition (DDA) in 
which a mass spectrum is acquired and analysed by the machine and, based on rules set by the user, 
certain ions – usually the top ten most abundant – are selected from that precursor mass spectrum 
(MS1) pre-scan and fragmented and their tandem mass spectra (MS/MS) measured (Watson & 
Sparkman, 2007). Orbitrap mass analysers are well suited for discovery experiments due to their ability 
to resolve complex mixtures of ions for high resolution results (Zubarev & Makarov, 2013). The 
product of a discovery phase is a list of analytes that show differences between various disease states. 
This is a semi-quantitative list and is likely to contain a certain percentage of false negatives and false 
positives (Rifai et al., 2006): a false positive is a candidate that upon further testing is not differentially 
expressed, and a false negative is a candidate that is differentially expressed but is not detected as 
such in the discovery phase. This list then proceeds to the verification phase of the experiment where 
it is refined.  
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Data independent acquisition (DIA) combines the indiscriminate data collection of full scan methods 
with the accuracy of targeted methods, and for such an experiment a quadrupole-quadrupole-time of 
flight (TOF) mass spectrometer is best suited (Gillet et al., 2012). A window of precursors, for example 
20 m/z units wide, is selected for fragmentation and a full scan is taken of all the fragment ions. The 
machine then moves onto the next window of precursors and cycles through in a systematic fashion 
until, theoretically, MS/MS data has been acquired for all species within a certain mass range. DIA 
experiments currently rely on spectral reference libraries generated on a shotgun mass spectrometry 
platform (Schubert et al., 2015). These libraries can also be used to validate targeted assays which are 
discussed below.  
A robust platform for the verification and refinement of candidate biomarker lists is targeted mass 
spectrometry. Targeted mass spectrometry is conducted with a priori knowledge of the analytes in 
question and is routinely performed on a triple-quadrupole mass spectrometer which offers high 
selectivity, sensitivity and a wide dynamic range. Precursor ions, representing target analytes, are 
selected in the first quadrupole and fragmented in the second. Product ions that have been 
preselected by the user are then filtered in the third quadrupole and their signal intensities are 
reported. These precursor-product ion sets are called transitions and in modern mass spectrometers, 
a transition set can be measured in a few milliseconds (Gillette & Carr, 2013), thus allowing tens to 
hundreds of transitions to be multiplexed per analysis. Such an experiment is called a multiple reaction 
monitoring (MRM) assay or selected reaction monitoring (SRM) assay, depending on the vendor or 
instrument. In this review MRM will be utilised, but it is interchangeable with SRM.  
1.3.1 MRM experiments 
MRM experiments are the gold standard method for analysing small molecules and have been used 
extensively in pharmaceutical and drug research (Hoke et al., 2001). MRM is a hypothesis driven 
experiment and prior knowledge of the molecule is required. Because of advances in mass 
spectrometry technology over the last decade, MRM experiments have begun to be applied to 
complex biological samples such as proteomes and metabolomes.  
When a triple-quadrupole mass spectrometer is operated in MRM mode, the first and third 
quadrupoles act as mass filters while the second quadrupole acts as a collision cell (Figure 1.1) (Gallien 
et al., 2011). An MRM experiment is ideal for measuring low level analytes in a complex biological 
mixture because of its ability to filter out much of the background noise. Fractionation, such as liquid 
chromatography (LC), usually precedes MRM experiments as it dramatically decreases the background 
signal and therefore increases the sensitivity of the measurements. 
 
Figure 1.1: Overview of a typical liquid chromatography mass spectrometry (LCMS) MRM experiment. 
When designing an MRM assay, the experimental question and target analytes are defined. Where 
possible, purified standards can be purchased for MRM development and used as a positive control. 
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If previous experiments have been done on the analyte, a library can be built and used to validate the 
MRM. For each analyte, the charge state and measured mass-to-charge ratio (m/z) is defined and then 
the fragment ions for each analyte are defined. Transitions are then optimised by tuning the machine 
to these values. If standards are being used, then the transitions can be validated by a dilution series 
where the measured signal is expected to decrease proportionally. This validation step also allows for 
the lower limits of detection (LLOD) and lower limits of quantification (LLOQ) to be determined for 
each analyte. Transitions can also be validated by assessing the retention time across multiple 
experiments. If standards are being used, it is ideal to validate transitions by spiking the standards into 
a complex biological matrix. This allows interference and noise to be assessed and the transition set 
refined accordingly.  
When a triple-quadrupole mass spectrometer is operated in MRM mode, all the machine’s analysis 
time is devoted to a small number of measurements. MRM assays will therefore provide a far more 
accurate quantitative measurement for each analyte than would be the case for a full scan or shotgun 
experiment, however, as stated, fewer analytes can be monitored per analysis. For quantification, the 
experiment must be optimised so that the mass spectrometer is able to measure between eight and 
ten points per chromatographic peak (Figure 1.2). Fewer measurements per peak can result in an 
inaccurate peak area reading (Agilent, 2007). Quantification by MRM assays is based on the signal 
intensity of specific transitions and can be done relatively or absolutely (Lange et al., 2008). In relative 
quantification experiments, the signal intensities for transitions are compared across multiple samples 
and results are reported as fold-changes rather than exact quantities. For relative quantification 
sample processing must be well controlled and sample matrices very similar. In absolute quantification 
experiments a known amount of isotopically labelled standard is spiked into the sample. The absolute 
amount of target analyte is then determined by its relative intensity to the heavy-labelled standard 
(Ankney et al., 2018). 
 
Figure 1.2: A demonstration of why eight to ten points per peak are required for accurate quantification. The three 
chromatograms on the left picture the real peak in black and the measured peak in red with too few points per peak. The far-
right peak pictures the correct peak shape being measured due to sufficient number of points per peak.  
To increase the number of analytes measured per analysis, scheduled MRM can be employed (Fillatre 
et al., 2010). In a scheduled MRM the transitions are only monitored when necessary according to 
prior knowledge about their LC retention times. Scheduled MRM decreases the number of transitions 
measured at any point in time, allowing more total measurements across a single experiment without 
compromising sensitivity.  
1.3.2 An introduction to high performance liquid chromatography (HPLC)  
HPLC makes the analysis of complex biological samples possible and therefore a mass spectrometry 
experiment is only as good as its preceding chromatography. 
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Reversed-phase HPLC is a method used to separate molecules based on their hydrophobicity. There 
are two phases involved; the mobile phase and the stationary phase. The stationary phase, or column, 
is made up of hydrophobic ligands to which molecules bind. The mobile phase is a solution that flows 
over the column and ranges from hydrophilic to hydrophobic. The separation of molecules depends 
on the binding of solute molecules from the mobile phase to the column. In reversed-phase HPLC, this 
binding happens in an aqueous mobile phase and the solutes are eluted by the addition of organic 
solvent to the mobile phase. The solutes therefore elute in order of increasing hydrophobicity, making 
it a powerful tool for the separation of complex biological samples (Aguilar, 2004). HPLC is a flexible 
method in which a wide range of chromatographic conditions can be employed and manipulated with 
relative ease.   
The HPLC system employed in this thesis consists of a C18-based stationary phase from which 
molecules are eluted by a mobile phase of increasing acetonitrile concentration. The mobile phase 
also contains an ion-pairing agent such as trifluoroacetic acid or formic acid, which assists with the 
retention of charged molecules on the stationary phase (Bidlingmeyer, 1980). The column is packed 
with microparticles of porous silica which are chemically modified to support a hydrophobic ligand. 
The most commonly used ligand is a C18 chain, however C4 and C8 chains are also employed and can 
provide alternative selectivity and separation (Zhou et al., 1991).  
Column dimensions depend on the level of efficiency that is required and generally resolution is 
proportional to column length (Jilge et al., 1987). The internal diameter is selected based on sample 
volumes and detection sensitivity. For most analytical applications an internal diameter of 4mm is 
employed, however if sample volumes are limited then an internal diameter of 1-2mm can be used to 
allow lower elution volumes. For further sensitivity nanoflow columns can be used which have internal 
diameters in the range of 75µm. Separation using nanoflow columns requires a longer gradient which 
subsequently increases analysis time (Hsieh et al., 2013), however the payoff is increased sensitivity 
and lower sample volumes required.  
HPLC is a versatile application because of the ease at which the mobile phase can be manipulated to 
optimise solute retention and resolution. The most routinely used organic solvents – usually mixed 
with water to different ratios – are acetonitrile, methanol and isopropanol (Aguilar, 2004) as they are 
nonreactive and do not interfere with the detection of the analytes. Acetonitrile has the lowest 
viscosity, which allows higher flow rates through the column which in turn decreases the experimental 
time, while isopropanol is the strongest eluent and is often used to clean columns between 
experiments.  1.4 Introduction to aims and methodology 
Metabolite changes occur before the onset of disease symptoms and these changes are often 
reflected in biofluids (Van et al., 2011). Urine has long been used as a non-invasive biofluid to detect 
abnormal metabolomic by-products, cells, bacteria, and hormones (Simerville et al., 2005). It is easy 
to collect, rich in metabolites, and is relatively stable ex vivo. One difficulty with urinary lipidomics, 
however, is that the expected concentration of complex lipids is relatively low (Rockwell et al., 2016), 
so extracts require additional concentrating steps. There are also multiple extraction methods and 
chromatographic conditions that favour specific lipid classes, some examples of which are shown in 
Table 1.1. A prior doctorate project within this laboratory has been done on the urinary lipidome to 
generate a list of candidate biomarkers to discriminate between latent and active TB infection 
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(Mlamla, 2018). Due to limiting scan times of the mass spectrometer used in that study, this discovery 
list was based on MS1 spectra only and few of the candidates have unambiguously assigned identities. 
For verification and quantification by mass spectrometry, it is important to transfer this list of 
candidates to a target-driven platform such as MRM assays. Chromatography must be identical to that 
of the previous experiment so that retention times can be used as a metric to match the MS1 values 
across experiments (Pabst et al., 2007). 
Table 1.1: Examples of the various lipid extraction and chromatographic methods in lipidomics.  
Extraction solvent Butanol: Methanol (1:1) 
Chromatography conditions C18 column, tetrahydrofuran, methanol, water, 10 mM ammonium formate 
Lipid class All major lipid classes. 
Reference Alshehry et al., 2015 
Extraction solvent Chloroform: Methanol (2:1) 
Chromatography conditions HILIC column, acetonitrile, methanol, water, 5 mM ammonium formate, 
0.05% ammonium hydroxide 
Lipid class Phospholipids, sphingolipids, glycerides, cholesterol esters, triglycerides, 
ceramides, glycosphingolipids and glycerophospholipids. 
Reference Bang et al., 2014 
Extraction solvent Methyl-tert-butyl ether: Methanol (2:1) 
Chromatography conditions C18 column, water, acetonitrile, methanol, isopropanol, 5 mM ammonium 
formate, 0.05% ammonium hydroxide 
Lipid class Phospholipids, sphingolipids, glycerides, triglycerides and 
glycerophospholipids. 
Reference Bang et al., 2014 
Extraction solvent Butanol: Methanol (3:1) and 
Heptane: Ethyl acetate (3:1), 1% acetic acid 
Chromatography conditions NA – direct infusion experiment 
Lipid class Cholesterol esters, free cholesterols, triacylglycerol, phosphatidylcholines, 
sphingomyelins, ceramides, diacylglycerols, and lyso-phospholipids. 
Reference Löfgren et al., 2012 
Extraction solvent Chloroform: Methanol (1:1) and Hexane: Isopropanol (3:2) 
Chromatography conditions NA – MALDI used 
Lipid class Phospholipids, sphingolipids, glycerides, triglycerides and 
glycerophospholipids. 
Reference Tipthara & Thongboonkerd, 2016 
 
The research reported in this thesis addresses the development of MRM assays to verify a list of 
biomarker candidates. This can be done with prior knowledge of the candidate molecules and thus 
synthetic standards can be used to create an MRM assay. Alternatively, it can be done de novo with 
no knowledge of the candidates’ identities. The aim of this project is to demonstrate two approaches 
in the generation of an MRM assay: namely 
1. Developing MRM assays for known lipid standards which can be employed in a complex 
mixture, and  
2. Developing MRM assays de novo to verify unidentified lipid biomarker candidates which 
can be applied in clinical cohorts for further validation. See Figure 1.3 for experimental 
overview. 
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Start with a list of known lipids, purchase standards.  
Use direct infusion on an orbitrap mass analyser to 
define charge state and MS1 values for each 
standard. 
Use direct infusion on a triple quad mass analyser to 
optimise source settings, collision energy, and 
product ions 
Use MS1 and MS/MS values to create an MRM method 
for each standard.  
Optimise chromatography.  
Validate MRM method by injecting variable 
concentrations of standard and assessing whether 
the changes are measured.  
Further validate MRM method by spiking standards into 
a complex mixture to assess sensitivity of the 
method. 
Start with a list of interesting MS1 candidates from previous 
experiments.  
Use iRT standards (developed in part 1) to correlate 
chromatographic conditions between past and current 
experiments.  
Use LC-MS/MS on an orbitrap in DDA mode with an 
inclusion list to generate MS/MS data for each 
candidate. Filter results.  
Use MS/MS data to generate MRM methods for candidates 
with MS/MS spectra.  
Test MRM methods and assess which fragments are co-
eluting with the precursor, and which fragments are 
background noise. 
Further refine MRM methods to a final MRM assay method.  
Validate MRM method by running on clinical cohort samples 
in duplicate. 
Figure 1.3: Experimental outline for 1) MRM development using standards (left in blue) and 2) MRM development of candidate biomarkers de novo (right 
in orange). 
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Chapter 2 – Development of MRM assays for lipids using standards 2.1 Introduction 
MRM assays are most commonly developed using purified standards, before proceeding to a complex 
mixture. This chapter describes the development of MRM assays for heavy labelled fatty acid 
standards, which are also to be used as retention time predictors in subsequent experiments.  
Heavy labelled fatty acid standards were selected because they are the basic building blocks of lipids 
and represent the stable carbon-chain associated with lipids (Sethi & Brietzke, 2017). Tocopherol 
acetate, more commonly known as vitamin E, was selected as it is a naturally occurring lipid with a 
complex head group and thus shares many fragmentation properties with biological lipids. See Figure 
2.1 for lipid standard structure and identity.  
 
 
 
 
 
 2.2 Aims 
The aim of this chapter was: 
1. To develop an MRM method for the analysis of lipid standards on a triple-quadrupole mass 
spectrometer, including optimising HPLC conditions and mass spectrometry settings for the 
measurement of the standards.  
2. To optimise conditions for both negative mode and positive mode mass spectrometry.  
3. To generate a work flow that can be applied to other future experiments using different standards.   
 
 
 
Figure 2.1: Structure of lipid standards. Hydrogens in the fatty acid carbon chains (except for Stearic acid) are replaced with deuterium, while 
ester group hydrogens are unchanged. Stearic acid carbons are replaced with 13C isotopes while the hydrogens remain in their light form. 
Tocopherol acetate is in its light form, i.e. unlabelled. 
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2.3 Experimental Procedures 2.3.1 Preparation and quality control of standards 
The following standards were purchased at 98% purity:  
 
Octanoic-d15 Acid (Sigma 55471) 
Lauric-d23 Acid (Sigma 451401) 
Myristic-d27 Acid (Sigma 68698)  
Palmitic-d31 Acid (Sigma 68277) 
Stearic 13C18 Acid (Sigma 89065) 
+/- α-Tocopherol Acetate (Sigma T3376) 
Standards were split into two samples, dried down with nitrogen gas, and resolubilised in each solvent 
system: chloroform : methanol (1:1) and isopropanol : hexane (70:30) to 1nmol/µl and stored at -20oC 
as the stock solutions.  
Standards were combined for each solvent system, with each standard at a final concentration of 
167pmol/µl in the mixture. This mixture was acidified with formic acid to a concentration of 0.1% and 
samples were then infused directly into a Q-Exactive quadrupole-Orbitrap mass spectrometer 
(Thermo-Fisher Scientific, USA) with a Hamilton syringe needle and electrospray ionisation (ESI) source 
at 5µl/min. Full scan MS1 data were acquired in both positive and negative mode using Xcalibur 3.0.63 
(Thermo-Fisher Scientific, USA). Fatty acids were observed in negative mode, and tocopherol acetate 
was observed in positive mode.  2.3.2 Compound optimisation on a triple-quadrupole mass spectrometer 
All standards were prepared individually in both chloroform : methanol (1:1) and isopropanol : hexane 
(70:30) solvent systems. Dilutions were made so that each standard was at 167pmol/µl, except for 
lauric acid which was prepared to 65nmol/µl, as it was found that an increased concentration was 
needed to allow visualisation of the compound. Samples were all acidified to 0.1% formic acid and 
directly infused into a Triple-stage Quadrupole Vantage mass spectrometer (TSQ; Thermo-Fisher 
Scientific, USA) using a Hamilton syringe and ESI source. Compound optimisation was done using TSQ 
Tune Master 2.5.0.1305 (Thermo-Fisher Scientific, USA) and MS/MS data acquisition was optimised 
using collision energy ramps from 0 to 80 eV.  2.3.3 HPLC trouble-shooting and optimisation 
Standards were prepared in both chloroform : methanol (1:1), and isopropanol : hexane (70:30) to 
1nmol/µl and all standards were acidified with formic acid to 0.1%. An EclipsePlus C18 Rapid 
Resolution High Definition (RRHD) 1.8µm 2.1 x 100mm (Agilent 959758-902) analytical column was 
used in conjunction with a C18 3mm guard column (Phenomenex AJ0-9000). Solvent A was water and 
0.1% formic acid, Solvent B was acetonitrile and 0.1% formic acid. HPLC optimisation was performed 
on the Thermo TSQ mass spectrometer as described in Section 2.3.2 with a micro-flow ESI source set 
to paramaters which were optimised in compound optimisation (Table 2.1).  
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Table 2.1: Thermo TSQ source parameters. 
Parameter Value 
Capillary temperature 320oC 
Vaporiser temperature 60oC 
Sheath gas pressure 10 bar 
Aux gas pressure 10 bar 
Positive polarity 3000V 
Negative polarity 3500V 
 
Each standard solution was analysed using a gradient that loaded at 0% Solvent B at 250µl/min and 
increased over seven minutes to 100% Solvent B where it remained for three minutes and then 
dropped back down to 0% Solvent B. Acidified standards were injected at 10nmol per analysis, 
however they were not observed using this chromatography. The loading conditions were changed to 
2% Solvent B and the rest of the gradient unchanged, however this did not improve the results.  
The HPLC configuration was altered so that the column was excluded but the loading conditions and 
source were not. The sample was collected by the autosampler and directed to the micro-flow source 
through empty tubing. The initial injection was done using an isocratic gradient of 2% Solvent B at 
250µl/min over five minutes and none of the standards were observed. The column-free injections 
were repeated with an isocratic gradient of 100% Solvent B at 250µl/min over five minutes and the 
standards were all observed except for lauric acid. Data were collected in full-scan MS1 mode and to 
confirm that the observed peak was the standard, a 10nmol and 20nmol injection was done for each 
standard in each solvent system. 
The HPLC configuration was returned to the standard method with the column in line with the 
autosampler and ESI source and the injections repeated with a 100% Solvent B isocratic gradient at 
250µl/min for five minutes. Each standard was acidified and injected in duplicate (once each, in each 
solvent system) and the loading concentrations of Solvent B altered for each gradient according to 
Table 2.2.  
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Table 2.2: Gradients employed to determine binding point of standards to C18 column. 
Gradient name Column volumes  Time (mins) % Solvent B Flow (µl/min) 
100% isocratic 3.5 0-5 100 250 
90% gradient 1 0-1.4 90 250 
 2 1.4-4.2 90-100 250 
 1 4.2-5.6 100 250 
 5 5.7-12.6 90 250 
80% gradient 1 0-1.4 80 250 
 3 1.4-5.6 80-100 250 
 1 5.6-7.0 100 250 
 5 7.1-14 80 250 
70% gradient 1 0-1.4 70 250 
 4 1.4-7.0 70-100 250 
 1 7.0-8.4 100 250 
 5 8.5-15.4 70 250 
60% gradient 1 0-1.4 60 250 
 5 1.4-8.4 60-100 250 
 1 8.4-9.8 100 250 
 5 9.9-16.8 60 250 
50% gradient 1 0-1.4 50 250 
 6 1.4-9.8 50-100 250 
 1 9.8-11.2 100 250 
 5 11.3-18.2 50 250 
40% gradient 1 0-1.4 40 250 
 7 1.4-11.2 40-100 250 
 1 11.3-12.6 100 250 
 5 12.7-19.6 40 250 
30% gradient 1 0-1.4 30 250 
 8 1.4-12.6 30-100 250 
 1 12.6-14 100 250 
 5 14.1-21 30 250 
20% gradient 1 0-1.4 20 250 
 9 1.4-14 20-100 250 
 1 14-15.4 100 250 
 5 15.5-22.4 20 250 
10% gradient 1 0-1.4 10 250 
 10 1.4-15.4 10-100 250 
 1 15.4-16.8 100 250 
 5 16.9-23.8 10 250 
5% gradient 1 0-1.4 5 250 
 11 1.4-16.8 5-100 250 
 1 16.8-18.2 100 250 
 5 18.3-25.2 5 250 
 
Thermo raw files were imported into Skyline 3.7.0 10940 (University of Washington, USA) where the 
document had been set up for small molecule analysis and the target transitions set according to the 
compound optimisation done previously in this project (Section 2.3.2). Anything eluting before one 
minute was considered dead volume and thus not interacting with the column. Standards that eluted 
later than one minute were interacting with the column and the gradient was plotted as a linear graph 
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of % Solvent B versus time. A delay of one minute was considered when back-calculating the % Solvent 
B at the point of elution.  
Based on the results from HPLC optimisation (Section 2.4.3), chloroform : methanol (1:1) was chosen 
as the preferred solvent system for solubilising fatty acid standards.   
The final HPLC gradient was optimised to start and load at 8% Solvent B for 3.5 minutes at a flow rate 
of 250µl/min. Solvent B increased to 100% over 28 minutes and remained at 100% for 7 minutes. 
Solvent B was decreased to 8% for 6.5 minutes, the equivalent of 2.5 column volumes, to re-equilibrate 
the column between experiments.  2.3.4 MRM assessment and validation  
Transitions were constructed for each standard based on the precursor-product ion pairs observed in 
the compound optimisation (see appendices, Table 5.1). The MRM method was created using Xcalibur 
3.0.63 (Thermo Fisher Scientific, USA), combining all transitions into one method.  
Standards were mixed into four different mixtures with altered concentrations as detailed in Table 
2.3. 
Table 2.3: Standard mixtures made up for injection. 
Standard Concentration 
Mix 1 
Concentration 
Mix 2 
Concentration 
Mix 3 
Concentration 
Mix 4 
Octanoic Acid 180 pmol/µl 400 pmol/µl 100 pmol/µl 100 pmol/µl 
Lauric Acid 6.9 nmol/µl 13.8 nmol/µl 3.4 nmol/µl 3.4 nmol/µl 
Myristic Acid 180 pmol/µl 100 pmol/µl 400 pmol/µl 100 pmol/µl 
Palmitic Acid 180 pmol/µl 100 pmol/µl 400 pmol/µl 100 pmol/µl 
Stearic Acid 180 pmol/µl 100 pmol/µl 100 pmol/µl 400 pmol/µl 
Tocopherol Acetate 91 pmol/µl 50 pmol/µl 50 pmol/µl 200 pmol/µl 
 
Each mixture was injected onto the column and measured by MRM using the Thermo TSQ mass 
spectrometer operated under the same conditions as described in section 2.3.3. Data was analysed in 
Skyline as previously described in section 2.3.3, and the transition sets were further refined to remove 
fragment ions that did not co-elute with the precursor ion.  
To validate the MRM in a complex matrix, lipids were extracted from healthy volunteer urine by 
aliquoting 5ml of urine and filtering through a 0.45µM filter and then a 0.22µM filter. Water : 
ethylacetate (5:7) with 6M HCl was added and the mixture vortexed for 30min. The urine sample was 
then centrifuged at 3320 x g for 10min. The supernatant was collected into a clean 50ml amber vial 
that had been weighed. This process was repeated an additional two times and the supernatants 
combined each time. The aqueous residue was mixed with 1ml of chloroform by gentle vortexing for 
30min. This was then centrifuged at 3320 x g for 10min and the supernatant combined with that from 
previous steps. This was repeated an additional two times and the supernatants combined each time. 
The aqueous residue was mixed with 1ml of methanol : chloroform (1:2) by gentle vortexing for 30min. 
This was then centrifuged at 3320 x g for 10min and the supernatant combined with that from 
previous steps. This was repeated an additional two times and the supernatants combined each time. 
The residue was mixed with 1ml of methanol : chloroform (1:1) by gentle vortexing for 30min. This 
was then centrifuged at 3320 x g for 10min and the supernatant combined with that from previous 
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steps. This was repeated an additional two times and the supernatants combined each time. 
Combined supernatants were dried down by vacuum centrifugation in the same pre-weighed amber 
vial as before. Dried extract was weighed, and the extraction yield determined by weight. Lipid extract 
was reconstituted in chloroform : methanol (1:1) and acidified to 0.1% formic acid for LCMS analysis.  
Standards were spiked into the urine lipid extract at the following concentrations: 
Octanoic acid – 250pmol/µl 
Lauric acid – stock depleted by this stage 
Myristic acid – 640pmol/µl 
Palmitic acid – 540pmol/µl 
Stearic acid – 250pmol/µl 
Tocopherol acetate – 50pmol/µl 
Urine lipid extract – 250ng/µl 
This mixture was injected at 20µl onto the column and measured with the Thermo TSQ mass 
spectrometer using the refined MRM method and HPLC gradient as in section 2.3.3. All data was 
analysed in Skyline as previously described in section 2.3.3. 2.4 Results and Discussion 2.4.1 Direct infusion on the Q-Exactive 
Standards were found to be soluble and ionizable in both solvent systems which allowed the charge 
state for each standard to be established. The fatty acids were observed with a charge state of -1 and 
tocopherol acetate was observed with a charge state of +1 (Table 2.4). Lauric acid was not detectable 
by direct infusion. The reasons for this may be that the ionisation conditions were not optimal for 
lauric acid, it was not in fact soluble in the solvent systems chosen, there may have been in-source 
fragmentation that was not detected, or the LLOD is significantly higher for lauric acid. Not too much 
time was spent on optimising conditions for lauric acid as it was not a critical component of this 
experiment. It did appear in later direct infusion experiments on the Thermo TSQ mass spectrometer 
where a higher concentration was infused. Formic acid was found to be a suitable ion-pairing agent in 
both positive and negative modes.  While it is acknowledged that acidic conditions are not the best 
for negative mode small molecule work (Wu et al., 2004), formic acid was suitable for the purposes of 
these experiments, and it was the ion-pairing agent used in the study (Mlamla, 2018) of which this is 
a continuation, so no further ion-pairing systems were tested. 
Table 2.4: Measured m/z values for each standard from the direct infusion experiment on the Q-Exactive. 
Standard Mass Mass + H Mass - H Observed m/z Charge state 
Octanoic Acid 159.30 160.30 158.30 158.201 -1 
Lauric Acid 223.46 224.46 222.46 222.30* -1 
Myristic Acid 255.54 256.54 254.54 254.371 -1 
Palmitic Acid 287.62 288.62 286.62 286.428 -1 
Stearic Acid 302.35 303.35 301.35 301.325 -1 
Tocopherol Acetate 472.74 473.74 471.74 473.399 +1 
*Lauric acid was observed at this m/z at a later stage during compound optimisation on the 
Thermo TSQ mass spectrometer. 
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2.4.2 Compound optimisation on the Thermo TSQ 
Masses from compound optimisation can be seen in Table 2.5 below and indicate a slight difference 
in precursor m/z from that measured on the Q-Exactive. Given that the data was generated using two 
different mass analysers, these slight differences in m/z are to be expected (Aebersold & Mann, 2003). 
The product ion measured for myristic acid was only 0.5 m/z smaller than the precursor. A mass shift 
of 0.5 m/z in MS1 spectra is commonly associated with doubly charged isotopes (Zhang & Marshall, 
1998) however, when looking at the MS1 spectra from the Q-Exactive direct infusion experiments, this 
253.9 m/z ion was not present and the isotopic envelope clearly showed a singly charged molecule 
(Figure 2.2). It may be that the precursor did not yield any measurable product ions in the compound 
optimisation experiment, and what is being measured here is an intact precursor, with a m/z shift 
caused by relatively poor resolution of the TQS mass spectrometer in full scan mode. If two peaks are 
separated by 1 m/z at high resolution, when the same molecule is measured at lower resolution the 
two peaks will merge and be measured as one peak. The apparent m/z measured on the low resolution 
mass spectrometer will be close to the average of the two isotope peaks.  
Table 2.5: Results from compound optimisation on the Thermo TSQ mass spectrometer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Precursor m/z Voltage (V) Cap. Temp. (°C) Product Ions 
m/z 
Collision 
Energy (V) 
Octanoic Acid 158,229 3500 350 137,9 
138,1 
16 
17 
Lauric Acid 222,3 3500 350 149,5 
164,9 
151,3 
6 
24 
45 
Myristic Acid 254,4 3500 350 253,9 12 
Palmitic Acid 286,5 3500 350 266,2 26 
Stearic Acid 301,3 3500 350 283,4 
283,0 
284,7 
212,8 
23 
24 
21 
61 
Tocopherol 
Acetate 
473,4 3200 320 165,1 
207,1 
147,1 
149,1 
137,1 
24 
19 
30 
28 
48 
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 2.4.3 HPLC trouble-shooting and optimisation 
The standards were observed in direct infusion experiments which confirmed they had not degraded 
and that they ionised sufficiently to be observed by mass spectrometry. However, when HPLC was 
introduced the standards disappeared, so troubleshooting was done to address the following options: 
A) there was a problem with the column, B) there was a problem with the loading conditions, or C) 
there was a problem with the source at high flow as the direct infusion was done at 5µl/min and the 
HPLC was at 250µl/min. A column-free injection was used to test option A), and the standards were 
still not detected. To test option B), the loading conditions were changed from 0% Solvent B to 100% 
which resolved the issue as the standards were observed again at 100% Solvent B. Therefore, it was 
not necessary to test option C.  
I hypothesise that the reason for this is that aqueous loading encourages micelle formation of the fatty 
acids (Blesic et al., 2007) thus making them undetectable by mass spectrometry. A micelle is an 
aggregate of fatty acids with the hydrophilic head regions in contact with the solution and the 
hydrophobic single-chain tail regions in the centre of the sphere (Figure 2.3). Micelles generally form 
in aqueous solutions, at moderate to high fatty acid concentrations, and are very difficult to detect 
with ESI mass spectrometry (Nohara et al., 1998).  
 
Figure 2.3: Schematic of a micelle formed by fatty acids in aqueous solution. 
Myristic acid 
m/z = 1 
Figure 2.2: Spectra from the full scan MS data acquired on the Q-Exactive. Heavy labelled myristic acid is seen at 254.37 m/z with 
its light isotope one unit smaller at 253.37 m/z. 
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After the standards had been observed in the column-free system, the injection was doubled from 
10nmol to 20nmol, and the peak intensities measured for each solvent system. It was found that the 
signal doubled from 10nmol to 20nmol, as expected, in the chloroform : methanol (1:1) solvent system 
but remained the same in the isopropanol : hexane (70:30) solvent system (Figure 2.4). This 
occurrence has not been recorded elsewhere in the literature, however it may be because the boiling 
points of chloroform and methanol are lower than the boiling points of hexane and isopropanol 
(Orgsoltab, 2017), which, in turn, means that the chloroform-methanol solvent mixture evaporates 
more readily in the ESI source than the isopropanol-hexane solvent mixture. Consequently, more 
sensitive measurements were observed in the former system than the latter. Because of this 
discrepancy, chloroform : methanol (1:1) was selected as the preferred solvent system for subsequent 
work.  
 
Figure 2.4: Signal intensity comparison of 10nmol injection versus 20nmol injection between chloroform: methanol (1:1) and 
isopropanol: hexane (70:30) solvent systems. The signal for each 20nmol injection was normalised to the corresponding 
10nmol injection (made to =1 in this graph). 
The column was reconnected and loading conditions tested from 100% Solvent B to 5% Solvent B to 
determine at which point the standards interacted with the column and at which point they 
disappeared from the gradient altogether. Figure 2.5 below is a representation of the elution time of 
each standard from the column using multiple different gradients. Lauric acid was loaded at a much 
higher concentration (~760nmol) which allowed it to be visualised. As can be seen from the graph, 
each standard begins to elute at a later point as the starting concentration of Solvent B decreases. This 
indicates column interaction which begins at a different point for each standard.  
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Figure 2.5: Stacked line graph of retention times for each standard on each gradient. 
 2.4.4 MRM assessment and validation 
Four different mixtures with an increasing range of individual standards were injected onto the 
column and analysed by MRM (Section 2.3.4). The retention times of the standards were measured in 
each experiment and plotted below in Figure 2.6. The retention times are clearly reproducible and the 
relationship between carbon chain length and retention time is proportional. This was to be expected 
and is a well-described trend (Tanaka et al., 1980). 
 
Figure 2.6: Measured retention time for each standard across four different injections. 
This experiment, with different concentrations of each standard injected per mixture, was found 
useful in determining the correct peak annotation. Occasionally false positives can be measured in 
MRM experiments and a way to test which is the true peak is to increase/decrease the injected 
amount of the analyte and identify which peaks increase or decrease proportionally. Peaks where the 
signal remains unchanged are a consequence of matrix interference. Results are shown in Figure 2.7 
below. Precursor ion (in blue) was used to compare signal changes between injections, and the 
fragment ion(s) (in colour) was/were used to confirm peak identity. The signal increases and decreases 
as expected for each standard, except for tocopherol acetate. According to the elution profile of the 
product ions, this is the correct peak as they are all measured and elute at the same time as the 
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precursor, however the changes in signal are not proportional to the injected amount. It is presumed 
that this is tocopherol acetate being measured, however it is particularly difficult to elute from the 
column, so the erroneous signal changes may be due to carryover. Stronger organic solvents in the 
mobile phase could potentially resolve this issue. For octanoic and lauric acids the product ions were 
difficult to measure, and the peak selection was done based on the precursor ions. This may be 
because the shortened carbon chain length yields less stable product ions when compared with the 
longer carbon chains. Octanoic acid also did not show a large signal increase when the injection was 
increased from 3.6nmol to 8nmol, however the 2nmol injections showed the expected signal decrease 
and there may have been an experimental error when Mix 1 was prepared in experimental section 
2.3.4.  
 
 
A:  Octanoic acid 
 
B:  Lauric acid 
 
C: Myristic acid 
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D: Palmitic acid 
 
E: Stearic acid 
 
F: Tocopherol acetate 
Figure 2.7A-F: MRM results for concentration changes of fatty acid standards across four different mixtures. Each figure is 
the integrated peak of precursor and product ions. 
To confirm that the MRM method designed in this section was applicable to a complex mixture, the 
standards were spiked into a lipid extract from urine prepared in section 2.3.4 and the results are 
shown in Figure 2.8 below. This extraction method (which is a modification of the well-known Folch 
method) was used so as to mimic the conditions of a previous study (Mlamla, 2018). An unspiked urine 
extract was also analysed with the same method to confirm the level of interference. Lauric acid was 
not spiked as the stock had depleted by this stage of the experiment. Octanoic, myristic, palmitic and 
stearic acids all gave convincing evidence that an MRM assay had successfully been generated with 
minimal interference in a biological matrix. Tocopherol acetate showed an increased signal in the 
unspiked sample versus the spiked sample which indicates that this may be due to a contaminant 
which shares the same mass as tocopherol acetate. This is also consistent with the previous evidence 
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showing that tocopherol acetate MRM results were not proportional to the spiked concentrations, 
and hence the MRM assay for this analyte is considered unreliable. This finding further confirms the 
importance of validating an MRM assay before using it for quantitative experiments.  
 
 
A: Octanoic acid 
 
B: Myristic acid 
 
C: Palmitic acid 
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D: Stearic acid 
 
E: Tocopherol acetate 
Figure 2.8A-E: MRM results from standards spiked in a complex mixture of lipids extracted from urine. The left panel 
represents the urine lipid extract which was spiked with standards, and the panel on the right is the urine extract unspiked 
to serve as a negative control. 2.5 Conclusions 
This chapter demonstrated the methodology used to generate an MRM assay for an analyte for which 
a commercial standard is available. Given the broad retention time range, this specific set of MRM 
assays can further be used for cross-column calibration or as an internal retention time predictor. This 
Chapter also demonstrated the importance of all validation steps when generating an MRM assay as 
not all candidate analytes will be suitable for MRM analysis. These methods can be applied to any 
biomolecule for which there is a commercially available standard.  
This Chapter also demonstrated that when working with fatty acids, one must be aware of micelle 
formation and therefore highly aqueous loading solutions should be avoided. 
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Chapter 3 – Verification of biomarker candidates 3.1 Introduction 
A list of some 2000 lipid biomarker candidates have already been generated based on a urinary 
lipidomic discovery experiment (Mlamla, 2018). Shotgun mass spectrometry was used to acquire MS1 
values for these biomarker candidates across three different patient groups namely:  
1. active TB infection,  
2. latent TB infection, and  
3. non-TB lung infection as a control group.  
Pairwise comparative analysis identified statistically significant lipids across these three groups, and 
these lipids created a metabolomic pattern that differentiated the three groups from each other. 
Hierarchical Cluster analysis showed marked differences in the expression levels of several molecular 
features between the patient groups. This list was refined to 70 of the most statistically significant 
biomarker candidates and this is the list that is verified in this Chapter. None of these biomarker 
candidates have their identities or structures confirmed due to no fragmentation data being acquired 
in the previous study; a limitation of the MS/MS cycle time on the Agilent qTOF 6530 used in that 
work. 
These biomarker candidates are described at the MS1 level; however, MS/MS data is required to 
differentiate a biomarker candidate from similar but separate molecules.  Compared with the uniform 
fragmentation of peptides along the amine backbone, metabolites and lipids do not fragment in a 
predictable way and they often yield common fragments (Herzog et al., 2011). Simple DDA 
experiments are not good enough to unambiguously match product ions to precursor as it is difficult 
to define what is noise and what is a product ion without being able to predict the fragmentation 
patterns, which requires a spectral library. Even with a library and an MS/MS spectrum it is often 
difficult to entirely characterise a small molecule. MRMs are required so that retention times can be 
used to link product ions to precursors using peak shape matching.  
As discussed in the literature review (Section 1.3.1), MRM assays are a highly selective and sensitive 
mass spectrometry technique and an excellent method for verifying biomarker candidates. This 
Chapter describes the process of progressing from shotgun data to refined MRM assays which can 
then be applied to future biomarker validation.  3.2 Aims 
The aim of this Chapter is to demonstrate a framework to generate MRMs for biomarker candidates 
de novo without standards or prior knowledge of the molecule. The secondary aim is to generate 
MS/MS data for a panel of biomarker candidates previously measured in the urine of TB patients 
(Mlamla, 2018). This chapter does not infer biological significance of the biomarker candidates, but 
rather creates refined MRM assays for as many candidates as possible.    3.3 Experimental Procedures 3.3.1 Cross-column calibration 
Biomarker candidates were originally discovered in 2014 using a Phenomenex Aqua 3µm C18 100 x 
3.0mm column coupled to an Agilent qTOF 6530 mass spectrometer, however the present body of 
work was conducted using an Agilent EclipsePlus 1.8µm C18 100 x 2.1mm column, hereafter referred 
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to as “Aqua” and “Plus” respectively. The reason for the column change is that the Aqua column was 
no longer performing optimally, and the closest column available was the Plus column. Given that 
MS/MS data had not been generated for the candidate biomarkers, retention time was used as a 
metric to support the premise that the MS1 measurement in the validation experiment corresponded 
to the MS1 measurement in the discovery experiment. A calibration was required between the two 
columns so that the retention times of the candidates could be predicted in the validation experiment.  
A mixture of standards was created using octanoic acid, lauric acid, myristic acid, palmitic acid, stearic 
acid and tocopherol acetate, from the same source as those used in Chapter 2. The standards were 
solubilised in chloroform : methanol (1:1) and acidified to 0.1% formic acid.  
The standard mix was injected onto each column and separated as described below. Both columns 
were heated to 40oC and connected to a C18 3mm guard column (Phenomenex AJ0-9000). The 
gradient that was used to generate the original list of candidate biomarkers is detailed in Table 3.1 
and the equivalent gradient which was used on the Plus column is detailed in Table 3.2. Solvent A was 
water acidified to 0.1% formic acid, and Solvent B was acetonitrile acidified to 0.1% formic acid. The 
second gradient was adapted so that the ratio between the column volumes and change in %B was 
the same in both gradients (Table 3.2).  
Table 3.1: Original gradient used in biomarker discovery experiment with the Aqua column. 
Column Volumes Time (mins) % Solvent B Flow (µL/min) 
2.5 0-5 8 350 
10 5-25 8-61 350 
5 25-35 61-80 350 
5 35-45 80-100 350 
5 45-55 100 350 
2.5 55.1-60 8 350 
 
Table 3.2: Adjusted gradient used on the Plus column. 
Column Volumes Time (mins) % Solvent B Flow (µL/min) 
2.5 0-3.5 8 250 
10 3.5-17.5 8-61 250 
5 17.5-24.5 61-80 250 
5 24.5-31.5 80-100 250 
5 31.5-38.5 100 250 
2.5 38.6-45.0 8 250 
 
Analytes were ionised using a Thermo Ion Max Source operated in ESI mode, and data was acquired 
using a Thermo TSQ mass spectrometer in MRM mode, with a cycle time of 3s, a total of 22 transitions 
and an average peak width of 0.70 FWHM. Data were acquired using Xcalibur 3.0.63 (Thermo Fisher 
Scientific, USA). 
Standards were analysed on both the previously used Aqua and the newer Plus columns on the 
gradients described in Table 3.1 and Table 3.2 respectively. The standards’ retention times from each 
experiment were plotted on X- and Y-axes as a linear graph, providing an equation that can be used 
to predict the retention time correlation between the two columns.  
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3.3.2 Clinical groups 
Patient urine samples had previously been stratified according to disease status: active TB disease 
(ATB), latent TB infection (LTBI), and non-TB lung infection (NTB) (Figure 3.1). ATB disease was defined 
as patients with a positive result for the presence of Mtb in culture and smear tests, as well as the 
patient displaying characteristic clinical symptoms of TB infection. The ATB group was further split into 
those who tested positive for the presence of LAM in urine (LAMp) and those who tested negative for 
the presence of LAM in urine (LAMn). LTBI was defined as asymptomatic patients who had tested 
negative for Mtb in culture and smear tests but had tested positive on interferon gamma release assay 
(IGRA). NTB patients were defined as patients who tested negative in IGRA and tuberculin skin tests, 
as well as negative in TB smear and culture tests, but had a positive diagnosis for another respiratory 
disorder. Urine was collected from patients and stored at -80oC prior to extraction. 
 
 
 
 
 
 
 
 3.3.3 Preparation of clinical urine extract 
Lipids were extracted from urine by aliquoting 5ml of urine and passing through a 0.45µM filter and 
then a 0.22µM filter. Water : ethylacetate (5:7) with 6M hydrogen chloride was added and the mixture 
vortexed for 30 minutes. The urine sample was then centrifuged at 3320 x g for 10min. Supernatant 
was collected into a clean 50ml amber vial that had been pre-weighed. This process was repeated two 
more times and the supernatants combined each time. A diverse set of organic solvents were added 
to the residue from the previous step and after each addition the sample was vortexed for 30min, 
centrifuged at 3320 x g for 10min, and the supernatants combined with that from previous steps. This 
was performed three times for each organic solvent in the following order: 
1. methanol : chloroform (2:1) with 14µM potassium chloride 
2. chloroform;  
3. methanol : chloroform (1:2);  
4. methanol : chloroform (1:1).  
Combined supernatants were dried down by vacuum centrifugation in the same pre-weighed amber 
vial as before. Dried extract was weighed, and the extraction yield determined by weight. Lipid extract 
was reconstituted in chloroform: methanol (1:1) and stored at -25oC until further use.  
LAM Negative 
(LAMn) 
Tested negative 
for LAM in urine 
LAM Positive 
(LAMp) 
Tested positive for 
LAM in urine 
Active TB (ATB) 
• Tested positive for Mtb in culture and 
smear testing  
• Displaying clinical TB symptoms 
Latent TB Infection (LTBI) 
• Tested positive on interferon 
gamma release assay 
• No clinical symptoms 
displayed 
Non-TB Infection (NTB) 
• Tested negative for TB in 
smear and culture testing 
• Displaying clinical symptoms 
of lung infection 
• Negative in IGRA a 
tuberculin skin tests 
Figure 3.1: Patient stratification according to clinical groups. 
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3.3.4 Preparation of pooled samples 
Nine pools were created by aliquoting 80µg of lipid extract from each sample and combining them 
according to Table 3.3. All the pools were dried down and the concentration corrected to 4µg/µl. The 
pools were acidified to 0.1% formic acid for LCMS analysis.  
Table 3.3: Pools created from urinary lipid extracts of clinical samples. 
ATB pools Samples LTBI pools Samples NTB pools Samples 
LAMp1 
 
TB_144 
TB_167 
TB_137 
TB_145 
LTBI1 LT_10 
LT_12 
LT_15µA 
LT_18 
NonTB1 NT_LAMP157 
NT_L257 
NT_L280 
NT_L283 
LAMn2 
 
TB_122 
TB_133 
TB_N340 
LTBI2 LT_10µA 
LT_12µA 
LT_13µA 
LT_20 
LT_21 
LT_37 
NonTB2 NT_1 
NT_17 
NT_5 
NT_9 
LAMn3 
 
TB_N134 
TB_N51 
TB_TS121 
LTBI3 LT_4 
LT_5 
LT_7 
LT_8 
LT_12 
NonTB3 NT_L029 
NT_L060 
NT_L261 
NT_L281 
NT_L259 
 3.3.5 Data-dependent MS/MS data acquisition on the Q-Exactive 
A total of 80µg lipid extract was injected onto the Plus column and the gradient employed as 
previously described in Table 3.2, section 3.3.1. Analytes were ionised using a Thermo Ion Max Source 
operated in negative or positive ESI mode and data was acquired using the Thermo Q-Exactive 
operated in data-dependent mode with inclusion lists. Full MS1 resolution was 70,000 and the 
maximum injection time (IT) was 100ms. The resolution for MS/MS was 17,500, the maximum 
injection time was 50ms, the loop count was 10, the isolation window was 4.0 m/z and the collision 
energy set to 35. Four inclusion lists were created based on the biomarker candidates originally 
observed in each sample subset: Active TB positive mode, Active TB negative mode, LTBI positive 
mode, and LTBI negative mode. Additionally, a method was used with no inclusion list for the NTB 
samples where no biomarker candidates were expected. Refer to Table 5.2 in the appendices for the 
full inclusion lists.  
Each pool was analysed with the inclusion list of biomarker candidates that were previously seen in 
that cohort (Table 3.4). A separate injection was done for positive mode, and for negative mode. 
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Table 3.4: Sample pools analysed according to their corresponding inclusion lists. Please see Table 5.2 in the appendices for 
further information on the inclusion lists. 
Sample Pool Inclusion lists 
LamP1 1. Active TB (positive mode) 
2. Active TB (negative mode) LamN2 
LamN3 
LTBI1 1. LTBI (positive mode) 
2. LTBI (negative mode) LTBI2 
LTBI3 
NonTB1        DDA mode only; no inclusion list 
NonTB2 
NonTB3 
 
Data was processed in Xcalibur 2.2 (Thermo Fisher, 2011). Using the Chromatogram Ranges function, 
full MS/MS spectra for each biomarker candidate precursor were extracted and the top ten intense 
m/z values selected as a set of preliminary MRM transitions. Of the 70 biomarker candidates, 13 were 
measured with MS/MS spectra and thus proceeded to the preliminary MRMs. In many cases the 
precursor that was measured was not exactly the mass that was expected and a maximum deviation 
of 0.09 m/z units from the original mass was allowed. These minor deviations are expected as the 
Agilent qTOF 6530 has a mass accuracy of 5ppm while the Q-Exactive has a mass accuracy of 1ppm. 
For example, the biomarker candidate 146.0927 was in the inclusion list, however an ion of m/z 
146.1185 was observed in one pool, and an ion of m/z 146.0865 observed in another. Both ions 
proceeded to preliminary MRMs as separate transition sets. Please see Table 5.3 in the appendices 
for the transition sets applicable to each sample pool. 3.3.6 Preliminary MRM development on the Thermo TSQ 
Transition sets were assembled into MRM assays for each sample pool and these were refined using 
the same sample pools as the DDA experiment. Pools were prepared as previously described in section 
3.3.4, with the exception that 100µg of lipid extract was injected onto the Plus column and the 
gradient was employed as previously described in Table 3.2, section 3.3.1.  
Analytes were ionised using a Thermo Ion Max Source operated in ESI mode with polarity switching, 
and data acquired using the Thermo TSQ mass spectrometer in MRM mode with a cycle time of 3s, a 
maximum of 35 transitions per method, collision energy of 35, and an average peak width of 0.70 
FWHM. Where there were more than 35 transitions per pooled sample, the transition set was divided 
over two or three methods (i.e. two or three separate injections) to maximise the points per peak as 
these were unscheduled experiments. LAMp1 had a total of 71 transitions targeted over two methods; 
LAMn2 had a total of 69 transitions targeted over two methods; LAMn3 had a total of 33 transitions 
targeted using a single method; LTBI1 had a total of 22 transitions targeted using a single method; 
LTBI2 had a total of 88 transitions targeted over three methods; LTBI3 had a total of 33 transitions 
targeted using a single method; NTB1 had a total of 88 transitions targeted over three methods; and 
NTB3 had a total of 33 transitions targeted over a single method. These transition sets are detailed in 
Table 5.3 in the appendices. 
Data were analysed in Skyline 3.7.0.10940 (University of Washington, 2015). Transition sets were 
manually generated in Skyline using the small molecule manual insert function, and the raw MRM 
data from the Thermo TSQ were imported. Peaks were integrated according to the expected retention 
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time, which was calculated using the column calibration equation generated in section 3.3.1. Product 
ions that did not co-elute and form a uniform peak were excluded, thus refining each MRM to just a 
few transitions. Further, where there had been two slightly different MS1 m/z values for the same 
candidate biomarker, retention time and fragment ions were compared. For example, candidate 
biomarker 817.329 was observed with m/z 817.331 and 817.336 in the DDA experiment. These were 
both treated as separate transition sets in the preliminary MRM, but the results showed that 817.331 
and 817.336 had a common retention time of 16.9 minutes and shared common product ions, thus 
suggesting that they were in fact the same molecule. Therefore, these two separate transition sets 
were merged into one with a precursor m/z of 817.3.  
The output for this experiment was a final set of 68 transitions for 13 biomarker candidates. This was 
compiled into one scheduled MRM method.    3.3.7 MRM validation using clinical samples 
The final MRM method was validated using the following individual clinical urine extracts: 
LTBI group (n=13) NTB group (n=12) ATB group (n=8) 
LT_12    NT_LAMP157   TB_TS121 
LT_4   NT_L257   TB_167 
LT_10    NT_1    TB_137  
LT_8   NT_L283  TB_145  
LT_5   NT_17   TB_122 
LT_10µA  NT_5   TB_133 
LT_13µA   NT_L029  TB_N340 
LT_21   NT_L060  TB_N134 
LT_37   NT_L261   
LT_7   NT_L281   
LT_18   NT_L259   
LT_15µA   NT_9   
LT_20     
 
The extracts were prepared for LCMS analysis by correcting the concentrations to 5µg/µl in chloroform 
: methanol (1:1) and acidifying to 0.1% formic acid. Once prepared, 100µg of lipid extract was injected 
onto the Plus column and the gradient employed as previously described in Table 3.2, section 3.3.1. 
Analytes were ionised using a Thermo Ion Max Source operated in ESI mode with polarity switching, 
and data were acquired using the Thermo TSQ mass spectrometer in scheduled MRM mode with a 
cycle time of 2s, a total of 68 transitions scheduled over the 45-minute gradient, with a collision energy 
of 35, and an average peak width of 0.40 FWHM. This experiment was repeated under the same 
conditions two weeks later. In both analyses the sample order was randomised.  
Data were analysed in Skyline 3.7.0.10940 using the previously refined document. Peaks were 
integrated based on precursor and product ion alignment and where there was uncertainty, predicted 
retention time was used to integrate the correct peak.  3.3.8 Quality checks 
For all MRM experiments on the Thermo TSQ, machine performance was monitored using the 
standard mixture and MRM method described in the “Cross-column calibration” experiment (Section 
3.3.1). A standard mixture was analysed at the beginning of the sequence, after every 10 samples, and 
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once again after the last sample. Data were processed using Skyline where they were evaluated for 
peak area and retention time shifts. 3.4 Results and Discussion 3.4.1 Cross-column calibration 
Two columns were compared, and a cross-column calibration performed by drawing a line through all 
the retention time points which produced a linear equation (Figure 3.2). This regression equation can 
be used to predict the retention time of the biomarker candidates from the Plus column, based on 
their measured retention times from the Aqua column. This is an adaptation of the proteomic indexed 
retention time (iRT) method which uses peptides of known elution times to compare and calibrate 
different columns (S. J. Parker et al., 2015).  
 
Figure 3.2: Cross-column calibration results. A trendline (dotted line) was drawn through the points with the R-squared value 
and linear equation displayed on the graph. 3.4.2 Data dependent acquisition on the Q-Exactive 
The total number of biomarker candidates being screened was 70. There were 30 positive mode 
candidates and 40 negative mode candidates. The biomarker candidates were split into three groups 
based on their MS1 observations in the original discovery experiment: LTBI (21 candidates), Active TB 
and/or LTBI (24 candidates), and Active TB (25 candidates). Based on the DDA experiments, the LTBI 
group was refined to five possible candidates, the Active TB/LTBI group was refined to three possible 
candidates and the Active TB group was refined to five possible candidates. These candidates were 
considered possible based on the generation of MS/MS spectra and therefore their potential for MRM 
targeting. Biomarker candidates for which no MS/MS measurements were made were excluded from 
subsequent analyses. The possible reasons for MS/MS data not being acquired for 57 biomarker 
candidates are: 1) very low abundant molecules were not selected for MS/MS measurement due to 
compromised machine performance, i.e. a false negative results, 2) the mass error on the Agilent qTOF 
6530 generated MS1 measurements, which were used in the inclusion lists, but may not have 
accurately represented the mass of the molecule, 3) biomarker candidates present in few samples 
would fall below the LLOD in a pool of samples where they are significantly diluted, or 4) the larger 
lipids, likely to be glycolipids, degraded over the four years of sample storage. Table 5.3 in the 
appendices displays the masses observed in each group across all the pools.  
The observed MS1 m/z for each biomarker candidate was marginally different from the expected MS1 
m/z and this is to be expected, as the candidate list was identified using an Agilent qTOF 6530 whereas 
in this experiment a Thermo Q-Exactive Orbitrap machine was used. In some cases, the same 
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candidate was observed across different pools but with a marginally different MS1 m/z. When looking 
at the MS/MS spectra from these candidates, some of them had common spectra, suggesting that 
they may be the same molecule.  They were however all treated as separate molecules until further 
validation by MRM.  
It appears that positive mode ions and ions with smaller mass were favoured. The lipid samples that 
were used were extracted in 2014, and while they were stored at -25oC multiple freeze-thaw cycles 
would have occurred in that time. Literature suggests that freeze-thaw cycles have little effect on 
lipids in a sample (Zivkovic et al., 2009), but duration of storage leads to degradation and changes in 
the lipidome of a sample (Soyer, et al., 2010). Given that these samples were analysed four years after 
the lipids were extracted, some changes are to be expected, particularly in the larger more complex 
lipids. The tendency towards positive mode ions may have been because formic acid was used as the 
ion-pairing agent. Formic acid is a proton donor and is therefore more suited for positive mode ESI 
than negative mode ESI (Cech & Enke, 2001).  
The output from this experiment was a list of observed MS1 m/z values for 13 biomarker candidates, 
each with a subset of MS/MS values which will be referred to as transition sets. Please see Table 5.3 
in the appendices for these values. The transition sets which arose from each pool were compiled into 
an MRM experiment. Therefore, this experiment resulted in nine separate MRM methods; one for 
each of the pooled samples.  3.4.3 Preliminary MRM experiment on the Thermo TQS mass spectrometer 
The MRM methods generated in the DDA experiment needed to be verified to assess which biomarker 
candidates produced co-eluting product ions and if these molecules eluted at the expected retention 
times.  
3.4.3.1 LTBI biomarker candidates 
In the DDA experiment the LTBI biomarker candidate 146.0927 (+1) was measured in the LAMn3 pool 
as 146.1185 m/z and in the LTBI2 pool as 146.0865 m/z. Based on the discovery experiments and 
column calibration equation, this molecule was expected to elute in the dead volume and not interact 
with the column. The transition sets for these two observations were quite different, already 
suggesting that 146.1185 and 146.0865 are different molecules. The preliminary MRM supports that 
they are likely not the same molecule as 146.1185 eluted at 8.0min with four co-eluting product ions; 
and 146.0865 eluted in the dead volume with only one product ion being measured (Figure 3.3). Given 
the lack of evidence in the dead volume, the next earliest eluting molecule with fragmentation was 
considered. Therefore 146.1185 at retention time 8.0min with four product ions was selected as the 
MRM for this biomarker candidate.  
 
 
 
 
 
Figure 3.3: Chromatograms of the fragments from 146.0870 in the LTBI2 pool (left) and from 146.1185 in the LAMn3 pool (right). 
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In the DDA experiment the LTBI biomarker candidate 188.1999 (+1) was measured in the LTBI1 and 
LTBI3 pools as 188.1758 m/z; in the LTBI2 pool as 188.1759 m/z; in the NonTB2 pool as 188.1756 m/z; 
and in the NonTB3 pool as 188.1760 m/z. Based on the discovery experiments and column calibration 
equation this molecule was expected to elute at 9.8min. Peaks were observed at around 4min and 
10min for this molecule. The fragmentation pattern was the same at both time points suggesting that 
this is the same molecule however the differences in retention time suggest not (Figure 3.4). One 
explanation could be that these are structural isomers of each other and therefore interact with the 
column in different ways, but the literature suggests that a C18 matrix, as used here, does not achieve 
isomer separation and further separation methods would have been required (Damen, et al., 2014; 
Kozlowski, et al., 2015; Kyle et al., 2016). It is therefore feasible that these are different molecules, but 
are too similar to be filtered out by the machine’s mass error window.  
Looking at Figure 3.4 below, it seems the same molecule is being measured at 10min in LTBI1, LTBI2 
and NonTB3, while a similar chromatogram for a different molecule is being measured in LTBI3 and 
NonTB2 at ~4min. It seems this is not the same molecule in LTBI3 and NonTB2 because of the 
differences in fragmentation. Because of the uncertainty of the molecule eluting at ~4min, the peak 
at 10min was integrated with three product ions and selected as the MRM for this biomarker 
candidate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Chromatograms of the product ions for 188.1760 as measured in the LTBI1 pool (top left),  
 
 
Figure 3.4: Chromatograms of the product ions for 188.1760 as measured in the LTBI1 pool (top left), LTBI2 pool (top right), LTBI3 pool (middle 
left), NonTB2 pool (middle right), and NonTB2 pool (b ttom left). 
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The LTBI biomarker candidate 189.1348 (+1) had been observed in the DDA experiment in the LAMn2 
pool as 189.0654 m/z; the LTBI3 pool as 189.1598 m/z; the NonTB1 pool as 189.0655 m/z; the NonTB2 
pool as 189.0657 m/z; and the NonTB3 pool as 189.0658 m/z. Based on the discovery experiments 
and column calibration equation this molecule was expected to elute in the dead volume and have no 
column interaction. In the preliminary MRM, co-eluting product ions were found in the LAMn2 pool 
at 6.2min, in the LTBI3 and NonTB2 pools at 41.1min, and no co-eluting product ions were observed 
in the NonTB1 and NonTB3 pools. In Figure 3.5 below it appears that the same molecule was measured 
in LTBI3 and NonTB2 pools, however given the retention time it is improbable that this is the 
biomarker candidate of interest. Therefore, the fragment ions measured at 6.2min in the LAMn2 pool 
were integrated and selected as the transition set for this biomarker candidate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The LTBI biomarker candidate 233.0793 (+1) had been observed in the DDA experiment in the LTBI2 
pool as 233.1212 m/z. Based on the discovery experiments and column calibration equation this 
molecule was expected to elute at 3.5min. In this preliminary MRM, the fragments were observed at 
1.8min. As can be seen in Figure 3.6 these peaks are not well aligned, and this is not enough evidence 
to say they come from the same molecule. Despite the uncertainty, it was the best measurement 
obtained for this biomarker candidate and with caution this transition set was selected to be used as 
an MRM for further verification.  
 
  
 
   
 
 
 
 
 
Figure 3.5: Chromatograms for the product ions for 189.0650 as observed in LAMn2 (top left), LTBI3 (top right), and NonTB2 (bottom left) 
Figure 3.6: Chromatogram of the fragment ions for 233.1210 in the LTBI2 pool. 
42                                                                     MSc by Elizabeth Louise Waldron, University of Cape Town 
 
The LTBI biomarker candidate 332.3304 (+1) had been observed in the DDA experiment in the LAMn3 
pool as 332.2811 m/z. Based on discovery experiments and the column calibration calculations this 
molecule was expected to elute at 19.2min. In this preliminary MRM five co-eluting fragments were 
observed at 15.6min which was within the acceptable retention time range, so this transition set was 
accepted as the MRM for this biomarker candidate (Figure 3.7).  
 
 
 
 
 
 
 
 
3.4.3.2 Active TB/LTBI biomarker candidates 
The first biomarker candidate in this group is 284.3311 (+1) which was observed in the DDA 
experiment as 284.3318 m/z in the LAMp1 pool, as 284.2956 m/z in the LTBI2 pool, and as 284.2947 
m/z in NonTB1 pool. Based on the discovery experiment and the column calibration equation, this 
molecule was expected to elute at the very end of the gradient at around 40-45min. A very weak signal 
was detected in the preliminary MRM for co-eluting product ions in LAMp1 and NonTB1 at 41min 
(Figure 3.8). Even though the signal was so low and different product ions were observed in each 
sample pool, these were combined to form one MRM assay for further verification. The cause of the 
very weak signal may be that this molecule is present in only a few of the samples that make up each 
pool, meaning that it has been diluted significantly in the pooling process. This can only be confirmed 
by analysing individual samples with the same MRM transition set.   
 
 
 
 
 
 
The next biomarker candidate in the group is 403.2348 (+1) which was observed as 403.1794 m/z in 
the LAMn2 pool, as 403.1749 m/z in the NonTB1 pool, and as 403.1748 m/z in the NonTB3 pool in the 
DDA experiments. Based on the discovery experiment and the column calibration calculations, this 
molecule was expected to elute at 27.9min. In the preliminary MRM experiment a peak was detected 
at 28.6min in all three pooled samples (Figure 3.9). As can be seen in this figure, four product ions 
were co-eluting in the NonTB1 pool, while only two of these were co-eluting in the LAMn2 and NonTB3 
Figure 3.7: Chromatogram of the fragment ions for 332.2811 in the LAMn3 pool. 
Figure 3.8: Transition sets observed for biomarker candidate 284.3311 as measured in the LAMp1 pool (left) and the NonTB1 pool (right). 
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pools, where the signal was also very weak. The product ions measured in the NonTB1 pool were used 
to create a transition list for this biomarker candidate’s MRM assay.  
 
 
 
 
 
 
 
 
 
 
 
The next candidate in this group is 445.3637 (+1) which was observed in the DDA experiment in pool 
LAMp1 as 445.3675 m/z. The molecule was expected to elute at the end of the gradient at around 40-
45 minutes. No co-eluting peaks were seen in the preliminary MRM experiment, so this biomarker 
candidate was removed from the list of those eligible for MRM assay development.  
3.4.3.3 Active TB biomarker candidates 
Biomarker candidate 284.1939 (-1) was observed in most of the sample pools in the DDA experiment 
as follows: in LAMp1 as 284.1692 m/z, in LAMn2 as 284.1501 m/z, in LAMn3 as 284.1500 m/z, in LTBI1 
and LTBI2 as 284.1700 m/z, in NonTB1 as 284.1504 m/z, and in NonTB3 as 284.1512 m/z. The expected 
elution time of this molecule was 14.5min based on the discovery experiment and column calibration 
calculations. In the chromatograms (Figure 3.10), co-eluting fragments were measured in LAMp1, 
LAMn3 and LTBI2 at 12.4min. This is possibly the same molecule being measured in each pool as the 
transition sets overlap and the retention times are the same. The transition lists across the sample 
pools were combined to make one MRM assay for this candidate with a precursor mass of 284.1.  
 
 
 
 
 
 
 
 
Figure 3.9: Chromatograms for the biomarker candidate 403.2348 which was measured as 403.1790 in the LAMn2 pool (top left), and 
403.1750 in the NonTB1 (top right) and NonTB3 (bottom right) pools. 
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The next biomarker candidate in this group is 432.2241 (-1) which was observed in the LAMn2 pool as 
432.2025 m/z, the LTBI2 pool as 432.2033 m/z , the NonTB1 pool as 432.202 m/z, and in the NonTB3 
pool as 432.2039 m/z. Based on the column calibration calculations and the discovery experiment this 
molecule was expected to elute at 12.9min. Co-eluting fragment ions for this biomarker candidate 
were observed in the LAMn2 pool, the LTBI2 pool, and the NonTB1 pool at 10.6min (Figure 3.11). 
There was an overlap in the transition sets which suggests this is the same molecule, and the transition 
sets were combined to generate the final MRM for this candidate with a precursor mass of 432.2 (-1).  
 
 
 
 
 
 
 
 
 
 
 
The next biomarker candidate in this group is 685.4386 (+1) which was measured in the DDA 
experiment as 685.4362 m/z in the LTBI2 and LTBI3 pools, each with a slightly different subset of 
product ions. This molecule was expected to elute at the end of the gradient at around 40-45 minutes. 
In the preliminary MRM, co-eluting product ions were measured at 40.9min in the LTBI2 pool only and 
at a very low signal. It is possible that this signal is coming from a small number of samples in the pool, 
Figure 3.10: Chromatograms for biomarker candidate 284.1939 measured as 284.1690 in the LAMp1 pool (top left), as 284.15 in the 
LAMn3 pool (top right), and as 284.17 in the LTBI2 pool (bottom left). 
Figure 3.11: Chromatograms for biomarker candidate 432.2241 measured as 432.204 in the LAMn2 pool (top left), as 432.203 in the LTBI2 
pool (top right), and as 432.204 in the NonTB1 pool (bottom left). 
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which would explain the low signal intensity. The chromatogram and transition set that was selected 
for the MRM assay is shown in Figure 3.12.  
  
 
 
 
 
 
 
 
The next biomarker candidate was 785,3224 (-1) which was expected to elute at 26.1min according to 
the column calibration calculations and discovery experiments. In the DDA experiment it was observed 
as 785.3507 m/z in the NonTB1 pool. In the preliminary MRM experiment, no co-eluting product ions 
were measured in the NonTB1 pool at the expected retention time, however two co-eluting fragments 
were observed at 10.7min (Figure 3.13) and these were selected for future MRM validation, with the 
intention of excluding them later if their inclusion proved unhelpful.  
 
 
 
 
 
 
The next biomarker candidate in this group is 817.3290 (+1) which was expected to elute at 18.6min. 
In the DDA experiment two possible masses were observed in the LAMp1 pool; 817.3309 m/z and 
817.3313 m/z. In the LAMn2 pool the m/z 817.3361 was observed. The two precursor masses 
observed in the LAMp1 pool in the DDA experiment are likely the same molecule as these m/z values 
are 0.5ppm apart and the mass error of the Q-Exactive is ~1ppm (Strupat, et al., 2013). They were 
treated as such in the preliminary MRM and their MS/MS spectra from the DDA experiment were 
converged into the same transition list. Figure 3.14 below displays the chromatograms with the 
transition lists for each preliminary MRM experiment in LAMp1 and LAMn2 respectively. A peak was 
observed at 16.9min in both pools and some of the product ions overlapped which suggests that these 
are the same molecules. The product ion lists were combined to be used as the final MRM assay for 
this biomarker candidate.  
 
 
Figure 3.12: Chromatogram for biomarker candidate 685.4386 measured as 685.436 in the LTBI2 pool. 
Figure 3.13: Co-eluting product ions for biomarker candidate 785.3224 measured as 785.351 in NonTB1. 
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The final biomarker candidate in this group is 1273.6095 (+1) which was observed as 1273.613 m/z in 
the LAMp1 pool and as 1273.601 m/z in the NonTB3 pool. Based on the column calibration equation 
and results from the discovery experiment, this molecule was expected to elute at 31.5min. Three co-
eluting product ions were measured at 29.2min in the LAMp1 pool and were not observed in the 
NonTB3 pool. Figure 3.15 below pictures the chromatogram and transition set. 
 
 
 
 
 
 
 
The result from this preliminary MRM experiment was a tentative MRM assay for 13 biomarker 
candidates which needed to be put through further validation on individual samples, rather than 
pooled samples. This experiment also helped to filter out product ions that had been observed on the 
Q-Exactive orbitrap but were not observed on the Thermo TSQ mass spectrometer. The reason for the 
differences in MS/MS spectra may be because these two machines have different collision energy 
cells: the Q-Exactive uses a higher energy collisional dissociation (HCD) cell while the Thermo TSQ 
operates with a collision induced dissociation (CID) cell. HCD and CID both induce fragmentation by 
the same mechanism of raising the energy of the ions and forcing them to collide with neutral atoms. 
The difference is that HCD operates at a slightly higher energy than CID, and HCD occurs separate from 
the mass analyser cell. While both collision methods are similar, it is expected to see some differences 
in the fragmentation patterns (Demarque, et al., 2016). These results do show, however, that the 
fragmentation patterns are sufficiently consistent between the two cells to use them interchangeably.  
Another reason for the differences are that the product ions measured in the Q-Exactive were in fact 
a result of chemical noise, and not part of the biological molecule. Therefore it is important to validate 
any MRM that was generated using a full scan mass spectrometer, as it allows noise to be filtered out.  
Figure 3.14: Chromatogram for biomarker candidate 817.3290 measured as 817.3310 in the LAMp1 pool (left) and as 817.3360 in the LAMn2 
pool (right). 
Figure 3.15: Chromatogram for biomarker candidate 1273.6095 measured as 1273.6130 in the LAMp1 pool. 
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3.4.4 MRM verification using clinical samples 
At this stage, the MRM assays for each candidate biomarker had been generated using pooled samples 
that theoretically represented each patient group. This was a prudent way to minimise sample loss 
and machine analysis time while developing and refining the assays, however it is important to 
validate these MRM assays on individual samples as the pools may not be representative of the 
individual samples. The aim of this section of the study was to establish 1) how reproducible each 
MRM is by doing repeat injections, 2) how feasible it is to use each MRM for quantitation, 3) how 
variable the retention times are for each MRM, and 4) how prevalent the biomarker candidates are 
across this sample set. On the fourth point, it is difficult to predict the diagnostic ability of this set of 
biomarker candidates because of the limitations in the clinical samples: These samples were four years 
old at the time of measurement, so it is expected that the lipids have degraded or been modified over 
time. These samples were analysed in duplicate with the second batch undergoing LCMS analysis two 
weeks later than the first. It was found that from batch 1 to batch 2, the peaks consistently shifted to 
an earlier retention time. The type of variability between experiments is acceptable as retention time 
is not considered a fixed property and can vary slightly between experiments due to day-to-day 
fluctuations in room temperature or solvent batches.  
3.4.4.1 LTBI biomarker candidates 
The first biomarker candidate in this group is 146.119 (+1) which was targeted with the following MRM 
transition set: 
Precursor > Product ions 
146.119 (+1) > 74.06 
146.119 (+1) > 100.08 
146.119 (+1) > 102.09 
146.119 (+1) > 127.09 
 
The results for this MRM showed two clear peaks with the same fragmentation approximately 30 
seconds apart from each other. Each peak was present in some samples and not others, and some 
samples contained both peaks (Figure 3.16). It was decided that the later eluting peak at 8.9min be 
integrated as it was closer to the previously observed retention time. Where the integrated peak was 
present in one sample it was always present in the repeat injection showing that this MRM assay is 
reproducible. See Table 3.5 for a summary of results for this biomarker candidate. This molecule was 
observed in 7/8 ATB samples, in 11/13 LTBI samples, and in 12/12 NTB samples.    
Table 3.5: Results summary for 146.119 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
30/33 30/30 ~8.9 mins ~8.3 mins 8.5% 
 
 
 
 
 Figure 3.16: Peaks eluting for biomarker candidate 146.119. A peak was observed at either ~8.9 minutes (left), both ~8.3 and ~8.9 minutes (middle), or at just ~8.3 minutes (right). Blue peaks in the upper panels represent the precursor, while the bottom 
panels represent the product ions. 
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The next biomarker candidate in this group is 188.176 (+1) which was measured using the following 
MRM transition set: 
Precursor > Product ions 
188.176 (+1) > 90.95 
188.176 (+1) > 116.95 
188.176 (+1) > 141.96 
   
The results for this MRM showed one clear peak with co-eluting fragments at ~10.2min in the first 
batch, and then at ~9.7min in the second batch (Figure 3.17). Table 3.6 summarises the results for this 
candidate biomarker’s MRM assay which was observed in 8/8 ATB samples, 8/13 LTBI samples, and 
7/12 being in the NTB samples. 
Table 3.6: Results summary for 188.176 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
23/33 23/23 ~10.2 mins ~9.7 mins 10% 
 
 
 
 
 
 
 
The next biomarker candidate in this group is 189.0 (+1) which was analysed using the following MRM 
transition set: 
Precursor > Product ions 
189.0 (+1) > 130.09 
189.0 (+1) > 131.98 
189.0 (+1) > 144.05 
189.0 (+1) > 161.07 
189.0 (+1) > 171.06 
   
The results for this MRM showed one clear peak with co-eluting product ions at ~6.6min in the first 
batch, and then at ~5.6min in the second batch (Figure 3.18). Where the integrated peak was present 
in one sample it was present in the repeat injection except for in sample NT_L157 where the first 
injection showed no peaks for this biomarker candidate, and the repeat injection showed a convincing 
peak. Each batch was freshly prepared for LCMS and sample handling in the first batch may have 
resulted in this analyte being degraded. Other MRMs were measured repeatedly in this sample, 
indicating that this specific analyte may be sensitive to perturbations while others are not. This 
biomarker candidate was observed in 3/8 ATB samples and in 2/13 LTBI samples with one 
irreproducible observation being made in one NTB sample. A summary of results for this candidate 
biomarker is detailed in Table 3.7. In previous work (Mlamla, 2018) this molecule was predicted to 
have the molecular formula C7H16N4O2. The most abundant product ion in this MRM is m/z 144.05 
Figure 3.17: An example of a peak for precursor 188.176 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 10.2 minutes in batch 1 (left), and at 9.7 minutes in the same experiment repeated two weeks later (batch 2; right). 
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which is consistent with the fragmentation of homoarginine and targinine (Mass Bank of North 
America, 2007), both of which share this chemical formula.   
Table 3.7: Results summary for 189.0 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
6/33 5/6 ~6.6 mins ~5.6 mins 6% 
 
 
 
 
 
 
 
 
 
 
 
 
The next biomarker candidate in this group is 233.12 (+1) which was targeted with the following MRM 
transition set: 
Precursor > Product ions 
233.12 (+1) > 128.95 
233.12 (+1) > 159.97 
   
The results for this MRM showed one clear precursor peak with co-eluting fragments at ~2.0min in 
the first batch, and then at ~1.7min in the second batch (Figure 3.19). The peak shapes for the 
fragments were not very well matched indicating that they may not originate from the same 
precursor. Where the integrated peak was present in one sample it was present in the repeat injection 
indicating that this MRM is reproducible. This biomarker candidate was observed in 1/8 ATB samples, 
in 7/13 LTBI samples, and in 3/12 NTB samples. The data for this MRM show a reliable measurement 
that is favoured in the LTBI group, however the shapes of the product ion peaks are a cause for caution. 
It would be advised that just one product ion (128.95 m/z) be used to measure this analyte as its shape 
closely matches the precursor ion shape. A summary of the results for this biomarker candidate are in 
Table 3.8. 
Table 3.8: Results summary for 233.12 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
11/33 5/6 ~2.0 mins ~1.7 mins 2% 
 
 
 
 
 
 
 
 
 
Figure 3.18: An example of a peak for precursor 189.0 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 6.6 minutes in batch 1 (left), and at 5.6 minutes in the same sample repeated two weeks later (batch 2; right). 
Figure 3.19: An example of a peak for precursor 233.12 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 2.0 minutes in batch 1 (left), and at 1.7 minutes in the same sample repeated two weeks later (batch 2; right). 
 
50                                                                     MSc by Elizabeth Louise Waldron, University of Cape Town 
 
The next biomarker candidate in this group is 332.281 (+1) which was measured using the following 
MRM transition set: 
Precursor > Product ions 
332.281 (+1) > 213.89 
332.281 (+1) > 225.89 
332.281 (+1) > 236.89 
332.281 (+1) > 251.89 
332.281 (+1) > 253.0 
   
The results for this MRM showed two peaks with co-eluting fragments at ~16.4min and at ~15.8min. 
While the earlier peak was closer to the expected retention time of 15.6min, its appearance was 
erroneous, and it was rarely present in both the sample and its repeat. The fragmentation of the peak 
at 15.8min was also inconsistent between samples, so the peak at 16.4min was selected for this MRM. 
Where the integrated peak was present in one sample it was present in the repeat injection indicating 
that this MRM is reproducible, however in sample TB_N134 the peak and its product ions were 
observed in the repeat, but not in the first injection. In the first injection for this sample, only the 
precursor ion was measured (Figure 3.20) while in the repeat inject the product ions co-eluted and 
formed clear peaks. While the MS1 intensity is similar in both experiments, the MS/MS intensity in 
the first repeat appears to fall into the noise signal. This may be why the product ion peaks are unclear 
and could have been a batch-specific machine error. This biomarker candidate was observed in just 
three of the 33 clinical extracts, with one observation in each clinical group. Table 3.9 summarises the 
results from this MRM assay.   
Table 3.9: Results summary for 332.281 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
3/33 2/3 ~16.4 mins ~15.8 mins 15% 
 
 
 
 
 
 
3.4.4.2 Active TB/LTBI biomarker candidates 
The first biomarker candidate in this group is 284.3 (+1) which was analysed using the following MRM 
transition set: 
Precursor > Product ions 
284.3 (+1) > 85.03 
284.3 (+1) > 95.09 
284.3 (+1) > 109.1 
284.3 (+1) > 230.12 
   
Figure 3.20: An example of a peak for precursor 332.281 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing in sample TB_N134 (left panel) and its repeat injection two weeks later (right panel). 
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The results for this MRM showed one peak at ~40.8min with the product ions present but not co-
eluting (Figure 3.21). This peak was not reproducible between the sample and its repeat, indicating 
that it is not a reliable MRM and should not be used to measure this biomarker candidate.  
 
Figure 3.21: An example of a peak for precursor 284.3 (top panel in blue) and the measured product ions (bottom panel in 
multicolours). 
 
The other biomarker candidate in this group is 403.17 (+1) which was targeted with the following 
MRM transition set: 
Precursor > Product ions 
403.17 (+1) > 69.03 
403.17 (+1) > 83.05 
403.17 (+1) > 120.06 
403.17 (+1) > 156.14 
403.17 (+1) > 160.14 
   
The results for this MRM showed a clear peak at 28.9min in the first batch and the same peak eluted 
at 28.0min in the repeat batch (Figure 3.22). In this MRM there appeared to be some interference on 
the MS1 scan, however at the MS/MS level a clear peak with co-eluting product ions was observed. 
Where the integrated peak was present in one sample it was present in the repeat injection indicating 
that this MRM is reproducible, however in sample NT_L157 the peak and its product ions were 
observed in the repeat, but not in the first injection. A similar inconsistency appeared in the same 
sample for one of the LTBI candidates (189.0) indicating that this may be more of a problem with the 
sample than with the MRM itself. This biomarker candidate was observed in 2/8 ATB samples, and in 
5/8 in the NTB samples. Table 3.10 summarises these results. 
Table 3.10: Results summary for 403.17 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
7/33 6/7 ~28.9 mins ~28.0 mins 28% 
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3.4.4.3 Active TB biomarker candidates 
The first biomarker candidate in this group is 284.1 (-1) which was measured using the following MRM 
transition set: 
Precursor > Product ions 
284.1 (-1) > 101.02 
284.1 (-1) > 109.04 
284.1 (-1) > 127.05 
284.1 (-1) > 128.03 
284.1 (-1) > 145.06 
   
The results for this MRM showed a clear peak at ~12.7min in the first batch and the same peak eluted 
at ~12.1min in the repeat batch (Figure 3.23). In this MRM there appeared to be some interference 
on the MS1 scan, however at the MS/MS level a clear peak with co-eluting product ions was observed. 
The product ion peaks are not identical in shape which may be caused by interference from other 
molecules; i.e. the product ions may be from two separate but similar precursors eluting at the same 
time. The product ion chromatograms are consistent and with no library available to make a 
comparison, it is impossible to decide which transitions to discard. Given the interference, it is 
recommended that this MRM just be used for presence/absence studies rather than quantification 
until the structure of this candidate biomarker can be elucidated, and a more accurate MRM 
generated. Where the integrated peak was present in one sample it was present in the repeat injection 
indicating that this MRM is reproducible. This biomarker candidate was observed in 8/8 ATB samples, 
in 9/13 LTBI samples, and in 9/12 NTB group samples. Table 3.11 summarises the results from this 
MRM assay.  
Table 3.11: Results summary for 284.1 (-1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
26/33 26/26 ~12.7 mins ~12.1 mins 12% 
 
 
 
 
 
Figure 3.22: An example of a peak for precursor 403.17 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 28.9 minutes (left panel) and at 28.0 minutes in its repeat injection two weeks later (right panel). 
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The next biomarker candidate in this group is 432.2 (-1) which was analysed using the following MRM 
transition set: 
Precursor > Product ions 
432.2 (-1) > 130.06 
432.2 (-1) > 133.07 
432.2 (-1) > 160.08 
432.2 (-1) > 204.07 
   
The results for this MRM showed a clear peak at ~10.9min in the first batch and the same peak eluted 
at ~10.3min in the repeat batch (Figure 3.24). In this MRM there appeared to be some interference 
on the MS1 scan, however at the MS/MS level a clear peak with co-eluting product ions was observed. 
In some cases, as can be seen in Figure 3.24 on the right panel, the product ions did not form the same 
peak shape. This only seemed to happen when the product ion intensity was very low (>500) so this 
may have been interference from noise rather than co-eluting precursors. This MRM did not show 
very high reproducibility; with a total of five samples having it present in the first batch and not the 
second. Where it was present in the repeat injection, the intensities were substantially lower than in 
the first injection. This biomarker candidate was observed in duplicate in 4/8 ATB samples, in 4/13 
LTBI samples, and in 8/13 NTB samples. Table 3.12 summarises the results for this MRM assay.  
 
Table 3.12: Results summary for 432.2 (-1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
15/33 10/15 ~10.9 mins ~10.3 mins 10% 
 
 
 
 
 
 
 
 
 
Figure 3.23: An example of a peak for precursor 284.1 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 12.7 minutes (left panel) and at 12.1 minutes in its repeat injection two weeks later (right panel). 
Figure 3.24: An example of a peak for precursor 432.2 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 10.9 minutes (left panel) and at 10.3 minutes in its repeat injection two weeks later (right panel). 
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The next biomarker candidate in this group is 685.436 (+1) which was targeted with the following 
MRM transition set: 
Precursor > Product ions 
685.436 (+1) > 72.89 
685.436 (+1) > 75.06 
685.436 (+1) > 184.33 
685.436 (+1) > 673.35 
   
The results for this MRM showed one peak in one sample at 40.8min (Figure 3.25). This same peak 
was not observed in the repeat injection, so it may have been there due to chance. This MRM should 
not be used to further measure this biomarker candidate as it is unlikely to be measuring anything of 
biological significance.  
 
 
  
 
 
The next biomarker candidate in this group is 785.35 (-1) which was targeted with the following MRM 
transition set: 
Precursor > Product ions 
785.35 (-1) > 113.02 
785.35 (-1) > 175.02 
   
The results for this MRM showed no peaks in any of the samples and very little consistency between 
experiments. This was somewhat expected as the results from the preliminary MRMs did not give 
strong evidence for this being the biomarker candidate.  
The next biomarker candidate in this group is 817.3 (+1) which was measured using the following MRM 
transition set: 
Precursor > Product ions 
817.3 (+1) > 95.05 
817.3 (+1) > 109.07 
817.3 (+1) > 123.08 
817.3 (+1) > 137.06 
817.3 (+1) > 151.08 
817.3 (+1) > 177.1 
817.3 (+1) > 179.11 
   
The results for this MRM showed a clear peak at ~17.1min in the first batch and the same peak eluted 
at ~16.4min in the repeat batch (Figure 3.26). Another peak appeared at 16.3min in some of the NTB 
Figure 3.25: The peak for precursor 685.436 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 40.8 minutes. 
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samples, however the ratio of product ions for this peak was different to that of the other observed 
peaks and this is therefore unlikely to be the same molecule. This MRM was reproducible with every 
observation being made in both the sample and its repeat. This biomarker candidate was observed in 
just three of the 33 clinical extracts, and all these observations were made in the ATB group. Table 
3.13 summarises the results from this MRM assay.  
 
Table 3.13: Results summary for 817.3 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
3/33 3/3 ~17.1 mins ~16.4 mins 17% 
 
 
 
 
 
 
 
 
The final biomarker candidate in this group is 1273.613 (+1) which was targeted according to the 
following MRM transition set: 
Precursor Product ions 
1273.613 (+1) 525.19 
581.25 
637.33 
   
The results for this MRM showed a clear peak at ~29.4min in the first batch and the same peak eluted 
at ~28.7min in the repeat batch (Figure 3.27). This MRM was somewhat reproducible as it was 
measured in 27 of the 33 samples, however in four of these samples it was not seen in duplicate. This 
biomarker candidate was observed in duplicate in 7/8 ATB samples, in 7/13 LTBI samples, and in 9/12 
NTB samples. Table 3.14 summarises the results for this MRM assay.   
Table 3.14: Results summary for 817.3 (+1) MRM assay. 
No. of samples observed in No. of repeat observations RT batch 1 RT batch 2 RT CV 
27/33 23/27 ~29.4 mins ~28.7 mins 29% 
 
 
 
 
Figure 3.26: An example of a peak for precursor 817.3 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 17.1 minutes (left panel) and at 16.4 minutes in its repeat injection two weeks later (right panel). 
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 3.5 Conclusions 
The final output of this Chapter are MRM assays developed for 10 out of 70 biomarker candidates, 
which were selected from an original list of ~2000 molecular features. This massive reduction in 
candidates is expected when progressing from biomarker discovery to verification (C. E. Parker & 
Borchers, 2014) and this list is expected to decrease further when this panel goes through final 
validation. Below, in Table 3.15, is a list of the final transitions for each biomarker candidate, with the 
expected retention time.  
The LTBI biomarker candidate, m/z 189.0, shared a common fragment, m/z 144.05, with homoarginine 
or targinine, chemical formula C7H16N5O2. Further work is required to validate this finding although it 
is an interesting one as homoarginine is an inhibitor of alkaline phosphohydrolase (Lin & Fishman, 
1972), and has been measured in urine, associated with liver disorders (Shoda et al., 1990; Shoda et 
al., 1988; Gatti & Gioia, 2008) and has also been associated with pulmonary disease (Bregy et al., 
2018). Alternatively, targinine is not a well-researched molecule and has been observed in blood or in 
food sources such as pulses and grains (Human Metabolome Database, 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.27: An example of a peak for precursor 1273.613 (top panel in blue) and its coeluting product ions (bottom panel in multicolours) 
appearing at 29.4 minutes (left panel) and at 28.7 minutes in its repeat injection two weeks later (right panel). 
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Table 3.15: Final transition sets for MRMs for the refined list of biomarker candidates. 
Biomarker class Precursor m/z Charge state Product ions Retention time 
LTBI 
146.119 +1 74.06 
100.08 
102.09 
127.09 
8.3 – 8.9 mins 
188.176 +1 90.95 
116.95 
141.96 
9.7 – 10.2 mins 
189.0 +1 130.09 
131.98 
144.05 
161.07 
171.06 
5.6 – 6.6 mins 
233.12 +1 128.95 1.7 – 2.0 mins 
332.281 +1 213.89 
225.89 
236.89 
251.89 
253.0 
15.8 – 16.4 mins 
LTBI / Active TB 
403.17 +1 69.03 
83.05 
120.06 
156.14 
160.14 
28.0 – 28.9 mins 
Active TB 
284.1 -1 101.2 
109.4 
127.05 
128.03 
145.06 
12.1 – 12.7 mins 
432.2 -1 130.06 
133.07 
160.08 
204.07 
10.3 – 10.9 mins 
817.3 +1 95.05 
109.07 
123.08 
137.06 
151.08 
177.1 
179.11 
16.4 – 17.1 mins 
1273.613 +1 525.19 
581.25 
637.33 
28.7 – 29.4 mins 
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Chapter 4 – Conclusions and Future Work 4.1 MRM assays for known standards 
The first part of this thesis (Chapter 2) developed MRM assays for heavy labelled standards. These 
standards can be used to absolutely quantify octanoic acid, lauric acid, myristic acid, palmitic acid and 
stearic acid in biologically derived samples. It was also found that in the case of all the standards, a 
longer C18 chain length was directly proportional to a later retention time. Therefore it is considered 
that this is an ideal set of standards for retention time prediction and cross-column calibration, as 
demonstrated in the experiment in Chapter 3.  4.2 MRM assays for biomarker candidates de novo 
The second part of this thesis (Chapter 3) aimed to develop MRM assays for biomarker candidates 
with unknown structure or identity. Initially 2000 molecular features were identified in a previous 
experiment and this list was refined to 70 of the statistically most significant candidate biomarkers. 
The methods employed in this thesis refined this list to 10 biomarker candidates which produced clear 
and reproducible MRM assay results. The methodology applied here can in principle be used to 
generate an MRM assay on any panel of unknown compounds. Because there are no standards 
available for these compounds, these MRM assays cannot be used for absolute quantification of the 
biomarker candidates but are suitable for relative quantification.  
This list of 10 candidates showed no molecule that performed well as a singular biomarker and the 
recommended end-point for this list would be a diagnostic panel able to measure unique 
biosignatures for different disease states.  Given the age of the clinical samples analysed, firm 
quantitative conclusions could not be drawn on each biomarker. 4.2.1 Biomarker development pipeline and future work 
In mass spectrometry-based proteomics, the biomarker pipeline progresses from discovery to 
verification to validation and finally to clinical evaluation (C. E. Parker & Borchers, 2014). These 
definitions will be applied to this lipidomic project as a similar logic is being followed. The discovery 
work for this project had been done previously where a priority list of 70 biomarker candidates was 
produced. The work described here achieved the verification of a subset these biomarker candidates 
where MRM assays were developed, and then tested for scheduling and reproducibility. The 
suggested next phase would be validation where a biomarker signature becomes associated with a 
known TB diagnostic outcome. This would require between 500 and 1000 fresh clinical samples 
(Surinova et al., 2011), stratified as they were in this project. Validation can take up to 12 months and 
the outcome is a defined biomarker panel for clinical evaluation. Clinical evaluation – the final phase 
– is where the test is evaluated in the intended patient population and the sensitivity and specificity 
of the test is defined.  4.2.2 Structural elucidation and identification 
The ability to generate an MRM for unknown compounds is important in the field of lipidomics and 
metabolomics, where molecule identification is time consuming, expensive, and requires high levels 
of expertise. This experiment refined a list of some 2000 compounds to a much more manageable list 
of 10 molecules of interest. For these MRM assays to be used for absolute quantification, they would 
ultimately need to be identified so that commercially available isotopically labelled standards could 
be used (Simpson et al., 2009).  
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Lipidomic identification and quantification remains a challenge given the complexity and diversity of 
lipid species. Isobaric species are common amongst lipids which means that MS1 identity alone is 
unreliable and further separation methods and fragmentation are necessary (Bielow et al., 2017; 
Hancock et al., 2017). The current methods for identifying lipids from shotgun mass spectrometry data 
are class-specific, use only MS1 values, or require prior knowledge of the lipid class being investigated 
(Husen et al., 2013; Kochen et al., 2016; Taguchi et al., 2007). Given that novel MRM assays for 10 
analytes result from this thesis, a targeted approach may be more appropriate in future studies.  
Mass spectrometry-based techniques could be coupled with two-dimensional orthogonal 
chromatographic separations to isolate the lipid compounds of interest (Zheng et al., 2018) with a 
further ion mobility spectrometry (IMS) step to characterise the lipids and separate lipid isomers 
(Baker et al., 2014). A significant challenge in structural elucidation of lipids is the verification and 
quantification of carbon-carbon double bonds. These bonds cannot be characterised in standard mass 
spectrometry experiments, and specialised fragmentation methods are required. Methods which have 
shown promise in the past are electron transfer dissociation (Liang et al., 2007), metastable atom-
activated dissociation (Li et al., 2016), electron-induced dissociation (Jones et al., 2015), radical-
directed dissociation (Pham et al., 2012), and ultraviolet photodissociation (Klein & Brodbelt, 2016). 
These techniques should be employed with caution however as data analysis is not standardised and 
requires a specialised expertise. Structural elucidation and identification of the lipids would be an 
important supplement to the data generated in this project, however such an endeavour is beyond 
the scope of a Masters Thesis.  
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Chapter 5 – Appendices 
 
Table 5.1: MRM transitions for each standard with collision energies, from compound optimisatio 
 
 
Compound Precursor m/z Voltage (V) Cap. Temp. 
(°C) 
Product Ions 
m/z 
Collision Energy 
(V) 
Octanoic Acid 158,229 3500 350 137,9 
138,1 
16 
17 
Lauric Acid 222,3 3500 350 149,5 
164,9 
151,3 
6 
24 
45 
Myristic Acid 254,4 3500 350 253,9 12 
Palmitic Acid 286,5 3500 350 266,2 26 
Stearic Acid 301,3 3500 350 283,4 
283,0 
284,7 
212,8 
23 
24 
21 
61 
Tocopherol 
Acetate 
473,4 3200 320 165,1 
207,1 
147,1 
149,1 
137,1 
24 
19 
30 
28 
48 
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Table 5.2: Inclusion lists targeted on the Q-Exactive. 
1. Active TB (pos) 2. Active TB (neg) 3. LTBI (pos) 4. LTBI (neg) 
Mass [m/z] CS [z] Polarity Mass [m/z] CS [z] Polarity Mass [m/z] CS [z] Polarity Mass [m/z] CS [z] Polarity 
284,33110 1 Positive 1059,04000 -1 Negative 146,09270 1 Positive 745,13820 -1 Negative 
304,29900 1 Positive 1088,12000 -1 Negative 188,19999 1 Positive 808,11750 -1 Negative 
320,29220 1 Positive 1159,16000 -1 Negative 189,13480 1 Positive 898,15220 -1 Negative 
403,23480 1 Positive 1206,06000 -1 Negative 233,07930 1 Positive 939,11020 -1 Negative 
445,36370 1 Positive 1218,14000 -1 Negative 284,33110 1 Positive 879,12630 -1 Negative 
707,28660 1 Positive 1220,13000 -1 Negative 304,29900 1 Positive 1191,77290 -1 Negative 
721,50060 1 Positive 1280,09900 -1 Negative 304,29970 1 Positive 1160,15960 -1 Negative 
974,57520 1 Positive 1282,09400 -1 Negative 320,29220 1 Positive 1148,09160 -1 Negative 
685,43860 1 Positive 1310,17000 -1 Negative 332,33040 1 Positive 1170,14310 -1 Negative 
792,33630 2 Positive 1399,22970 -1 Negative 403,23480 1 Positive 1177,17580 -1 Negative 
817,32900 3 Positive 1402,21400 -1 Negative 445,36370 1 Positive 1218,13370 -1 Negative 
899,60460 1 Positive 1291,09600 -1 Negative 707,28660 1 Positive 1170,14000 -1 Negative 
903,41370 1 Positive 1057,04400 -1 Negative 721,50060 1 Positive 1177,18000 -1 Negative 
935,50230 1 Positive 1071,13300 -1 Negative 959,96570 1 Positive 1218,13366 -1 Negative 
942,63360 1 Positive 1293,15200 -1 Negative 974,57520 1 Positive 1218,13688 -1 Negative 
972,47790 1 Positive 284,19400 -1 Negative    1340,07000 -1 Negative 
1023,55440 1 Positive 432,22400 -1 Negative    1374,85000 -1 Negative 
1184,50690 1 Positive 785,32200 -1 Negative    1059,04000 -1 Negative 
1273,60950 1 Positive 852,37400 -1 Negative    1088,12000 -1 Negative 
1293,60870 1 Positive 867,38400 -1 Negative    1159,16000 -1 Negative 
1296,58680 1 Positive 1075,42200 -1 Negative    1206,06000 -1 Negative 
1347,90420 1 Positive 1135,68400 -1 Negative    1218,14000 -1 Negative 
   1385,86720 -1 Negative    1220,13000 -1 Negative 
   1387,86000 -1 Negative    1280,09900 -1 Negative 
   1412,88330 -1 Negative    1282,09400 -1 Negative 
         1310,17000 -1 Negative 
         1399,22970 -1 Negative 
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         1402,21400 -1 Negative 
         1291,09600 -1 Negative 
         1057,04400 -1 Negative 
         1293,15200 -1 Negative 
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Table 5.3: Transition sets observed in each pooled sample in the DDA experiment. An MRM method was created for each pool based on these transition sets. 
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